Terminal2 — Card #00: [Diagnosis Name]

S01 Everyone

What Is It

Definition, mechanism, and the clinical reality of idiopathic pulmonary fibrosis at end of life. What the hospice team needs to understand on day one — a disease that replaces functional lung with scar tissue, relentlessly and irreversibly, with no mechanism in medicine to stop it.

US Prevalence

~200,000

IPF affects approximately 200,000 Americans with an estimated incidence of 50,000 new cases annually. Age-standardized incidence is rising 2–4% per year in developed countries, driven by an aging population — IPF predominantly affects individuals over 60, with highest incidence in the seventh and eighth decades.^[1] IPF is substantially underdiagnosed: autopsy series suggest fibrotic lung disease is present in 5–8% of individuals over 75 who died from other causes. The diagnostic delay from first symptoms to confirmed diagnosis averages 2–3 years, during which patients are commonly misdiagnosed with COPD, heart failure, asthma, or hypersensitivity pneumonitis.^[2]

Prognosis by GAP Stage

3–5 yr

The GAP index (Gender, Age, Physiology) is the most validated prognostic model for IPF. GAP Stage I (FVC >75%, DLCO >55%): median survival 5.6 years. GAP Stage II (FVC 50–75%, DLCO 36–54%): median survival 2.7 years. GAP Stage III (FVC <50%, DLCO <35%): median survival 1.4 years.^[3] The hospice-eligible patient is typically GAP Stage III with rapidly declining physiology, significant exertional hypoxemia, and either established pulmonary hypertension or a history of acute exacerbation. The overall 3–5 year median conceals extreme individual variation — some decline over months, some plateau for years.^[4]

Acute Exacerbation Mortality

50–80%

Acute exacerbation of IPF (AE-IPF) — acute respiratory worsening of unknown cause on a background of IPF — carries per-episode in-hospital mortality of ~50% and 90-day mortality of 50–80%.^[5] AE-IPF is the most feared complication and the leading cause of IPF-related death. It can occur at any GAP stage, in patients on antifibrotic therapy, and without any identifiable precipitant. Invasive mechanical ventilation for AE-IPF carries >85–100% mortality in most published series.^[6] The family must be prepared at enrollment for this possibility.

Hospice Eligibility

LCD Criteria

Dyspnea at rest or minimal exertion; VC <70% predicted; DLCO <40% predicted; resting SpO₂ ≤88% or exertional SpO₂ <88%; AND one or more: FVC decline >10% over 6 months, DLCO decline >15% over 6 months, acute exacerbation history, or pulmonary hypertension.^[7] Antifibrotic therapy does not reverse or stop IPF — it slows decline in approximately 50% of treated patients. The hospice-eligible patient has arrived at the point where slowing the decline is no longer enough to prevent the daily reality of progressive respiratory failure.

Idiopathic pulmonary fibrosis is a specific form of chronic, progressive, fibrosing interstitial pneumonia of unknown cause, occurring primarily in older adults, limited to the lungs, and associated with the histopathological and/or radiological pattern of usual interstitial pneumonia (UIP).^[8] The pathological process involves the activation of myofibroblasts — fibroblast-like cells that deposit excess collagen and extracellular matrix in the alveolar interstitium — producing the progressive replacement of functional gas-exchanging alveolar tissue with stiff, noncompliant scar tissue. No one knows why this process begins. No one has found a way to stop it. The word "idiopathic" in the diagnosis means "of unknown cause," and the patient who heard this word for the first time in a pulmonologist's office heard a sentence that offered no satisfying explanation for why their lungs are turning to stone.

The consequences of this replacement are devastating in their specificity: reduced lung compliance — the lungs become progressively stiffer and require greater inspiratory effort to inflate; reduced total lung capacity, functional residual capacity, and vital capacity — the patient has less lung volume to work with at every breath; impaired gas exchange — the thickened, scarred alveolar-capillary membrane impairs oxygen diffusion, with the diffusing capacity for carbon monoxide (DLCO) being the most sensitive physiological measure of this impairment, often severely reduced before significant symptoms appear.^[9] The profound exertional hypoxemia of IPF — where SpO₂ may drop from 93% at rest to 78% with minimal exertion — reflects the failure of the damaged alveolar-capillary membrane to maintain oxygen loading when cardiac output increases with exercise. Supplemental oxygen partially compensates at rest but cannot fully compensate during exertion as diffusion limitation becomes the dominant mechanism.^[10]

The clinical consequences for the hospice patient are: oxygen dependence that escalates relentlessly as fibrosis advances, often exceeding the capacity of home concentrators (reliably delivering only 5–6 L/min) and requiring compressed gas cylinders or liquid oxygen systems; exertional hypoxemia catastrophically worse than resting saturations suggest, requiring separate resting, exertional, and nocturnal oxygen prescriptions; the chronic refractory cough caused by mechanosensory activation of stretch receptors and irritant receptors in the fibrotic lung parenchyma, resisting virtually all available treatments and causing rib fractures, urinary incontinence, and sleep destruction; pulmonary hypertension developing in 30–60% of patients from hypoxic vasoconstriction and vascular remodeling, adding right heart failure to the clinical picture; and the acute exacerbation — an acute injury superimposed on the chronic fibrosis carrying extraordinarily high mortality with no proven effective treatment.^[11]

The antifibrotic era — initiated in 2014 with the FDA approval of both nintedanib (Ofev, INPULSIS trials) and pirfenidone (Esbriet, ASCEND trial) — represents a meaningful but not curative advance.^[12]^[13] Both drugs reduce the rate of FVC decline by approximately 50% compared to placebo, but neither stops the fibrosis, reverses existing lung damage, nor improves survival dramatically in most patients. The treated patient still declines, still reaches end-stage, and still dies from IPF. The hospice enrollment of an IPF patient does not necessarily mean antifibrotic therapy must stop — the decision requires explicit reassessment of goals, side effects, and remaining prognosis at the enrollment visit.

🧭 Clinical Framing

IPF is a disease of progressive replacement. The lungs that were elastic and compliant are being replaced, alveolus by alveolus, with stiff, non-functional scar tissue. The patient who sits across from you at enrollment is experiencing this replacement in real time — their breathing is slightly more labored this week than last, the oxygen flow rate that worked last month no longer holds their saturation, the cough that used to come in episodes now comes in sustained paroxysms that crack ribs. The hospice clinician who walks into an IPF home walks into a disease that defines every moment of every day through the act of breathing — the one act that cannot be put off, delegated, or rested from. Every visit must begin with the breath: is it harder today? Is the oxygen enough? Is the cough controlled? Is the exertional desaturation being managed? The IPF patient who is comfortable at rest but desaturating to 76% walking to the bathroom has not been adequately assessed. The IPF patient with resting dyspnea who is not on an opioid has not received adequate comfort management.^[14]

From the Field

Waldo Rios, NP

Hospice NP · 12+ Years

"My first IPF patient was a 68-year-old retired ironworker. Three years told it was COPD. Two more years told it might be hypersensitivity pneumonitis from the pigeons he kept. Finally diagnosed at 65, started on nintedanib that turned his GI tract into a disaster — but he took every pill because the pulmonologist said it was slowing things down. Two years on the transplant list. Two calls — one false alarm, one organ that went to someone sicker. Now at 15 liters per minute on a high-flow system, still desaturating to 82% walking to the bathroom. His wife hadn't left the house in months because she never knew when the coughing would produce the cracking sound that meant another rib. I sat at that kitchen table and I did not start with an assessment. I started by saying that his lungs have fought something that medicine has no way to stop. That the two years on the transplant list were not failure — they were hope that was legitimate and real. That what is left now is not defeat but a different kind of fighting, and my job is to figure out exactly what is making every moment harder and to remove as much of that hardness as medicine can reach."

— Waldo, NP · Terminal2

S02Clinician

How It's Diagnosed

IPF diagnostic criteria, HRCT patterns, pulmonary function test interpretation, and what to look for in hospice records. Most patients arrive with an established diagnosis — this section helps you read it and identify the clinical data that drives your comfort plan.

Diagnostic Workup — ATS/ERS/JRS/ALAT Criteria

The 2022 ATS/ERS/JRS/ALAT guidelines define IPF diagnosis through two mandatory criteria:^[8]

Exclusion of other ILD causes: Hypersensitivity pneumonitis, connective tissue disease–associated ILD, drug-induced ILD, and occupational ILD must be excluded by clinical history, serological testing, and exposure assessment
UIP pattern on HRCT: Typical UIP — honeycombing (with or without peripheral traction bronchiectasis), subpleural basal-predominant distribution, bilateral involvement. This is the radiological signature of IPF. Probable UIP — reticular pattern with traction bronchiectasis but no honeycombing, subpleural basal-predominant. Indeterminate for UIP — patterns not fitting typical or probable categories^[15]
Surgical lung biopsy (VATS): Reserved for indeterminate HRCT; UIP histopathological pattern shows temporal and spatial heterogeneity of fibrosis, honeycombing, and fibroblastic foci — provides definitive diagnosis when imaging is unclear^[16]
Multidisciplinary team (MDT) discussion: ATS guidelines require ILD multidisciplinary discussion (pulmonologist, radiologist, pathologist) for complex cases — the MDT report is the most authoritative diagnostic document in the record^[17]
Bronchoalveolar lavage (BAL): BAL in UIP pattern may show increased neutrophils and eosinophils; primarily used to exclude alternative diagnoses such as infection or eosinophilic pneumonia

Pulmonary function tests — the critical physiological data:

FVC (forced vital capacity): Primary measure of restrictive physiology; FVC <70% predicted is a hospice eligibility criterion; decline ≥10% over 6 months is a major adverse prognostic marker^[18]
TLC (total lung capacity): Reduced in restrictive disease; <70% predicted indicates significant restriction
DLCO (diffusing capacity for CO): The most sensitive gas exchange measure in IPF; DLCO <40% predicted is a hospice eligibility criterion; declines faster than FVC in many patients; best physiological correlate of exertional hypoxemia severity; decline ≥15% over 6 months is a major prognostic marker^[19]
FEV₁/FVC ratio: Typically normal or supranormal (>0.70) in IPF, reflecting restrictive rather than obstructive physiology. A reduced ratio suggests combined pulmonary fibrosis and emphysema (CPFE) syndrome

Six-minute walk test (6MWT):

Distance <200 meters at GAP III stage; exertional SpO₂ nadir is a critical datum — nadir <88% meets criteria for exertional supplemental oxygen; nadir <80% indicates severe desaturation requiring high-flow oxygen or ambulatory liquid oxygen^[20]
Desaturation distance — meters walked before SpO₂ drops below 88%; rate of SpO₂ recovery post-exercise — slower recovery indicates worse gas exchange reserve

What to Look for in Hospice Records

Confirmed IPF diagnosis with HRCT pattern: UIP typical, probable, or biopsy-confirmed; note the diagnostic certainty level — typical UIP on HRCT is the most definitive non-invasive diagnosis
Most recent FVC % predicted and 6-month trend: The rate of decline, not the absolute value, drives prognosis; a patient losing >10% FVC in 6 months is on an accelerating trajectory regardless of current absolute FVC^[18]
Most recent DLCO % predicted and 6-month trend: DLCO <40% predicted is the gas exchange threshold that defines severe impairment; decline ≥15% over 6 months is a critical marker
Most recent 6MWT with exertional SpO₂ nadir: This is the single most important datum for oxygen prescription — the gap between resting and exertional SpO₂ defines the oxygen management challenge
Current oxygen prescription — three separate values: Resting flow rate, exertional flow rate, and nocturnal flow rate. These are often different and all must be documented. If only one flow rate is listed, the patient's oxygen plan is incomplete^[21]
Oxygen delivery system: Home concentrator (max reliable delivery 5–6 L/min), compressed gas cylinders (portable ambulatory use), liquid oxygen system (higher flow rates, longer ambulatory duration), or HFNC (advanced refractory hypoxemia at 40–60 L/min)
Current antifibrotic medication: Nintedanib or pirfenidone — document current dose, documented side effects, current GI burden, and whether the patient reports ongoing benefit
Echocardiogram: Presence and severity of pulmonary hypertension (estimated RVSP), right heart function (RV dilation, tricuspid regurgitation severity)^[22]
Transplant status: Was the patient evaluated? Listed? Received a transplant? Removed from the list? What was the family's experience of the transplant process?
Acute exacerbation history: Number of episodes, dates, treatments attempted, outcomes — each prior AE-IPF increases the probability of recurrence
Advance directive status: Specifically addressing AE-IPF management (corticosteroids, NIV, invasive ventilation), hospitalization preferences, and ICU preferences
Cough severity and current management: What treatments have been tried and with what result — document systematically
Current dyspnea management: Opioid prescription or absence thereof — the IPF patient arriving at hospice without an opioid for dyspnea has not received adequate comfort management
Caregiver status and current capacity: The IPF caregiver burden is among the highest in respiratory disease — oxygen equipment management, cough crisis response, and AE-IPF vigilance produce sustained hypervigilance

CPFE syndrome — an important IPF variant to identify: Upper lobe emphysema coexisting with lower lobe fibrosis; preserved or near-normal FVC despite severe exertional hypoxemia; DLCO dramatically reduced out of proportion to FVC; higher rate of pulmonary hypertension; worse prognosis than IPF alone. The patient with "preserved" FVC but severe exertional hypoxemia and dramatically low DLCO likely has CPFE.^[23]

💡 For Families

💡 Para las familias

Your loved one's diagnosis of idiopathic pulmonary fibrosis was made through a combination of specialized lung imaging (high-resolution CT scan) and breathing tests. The word "idiopathic" means the cause is unknown — this is not a failure of diagnosis, it is the reality of this disease. Most of the diagnostic workup is complete before hospice enrollment. Our focus now is entirely on comfort — reading the test results your medical team has already gathered to build the best possible comfort plan for your person's specific situation.

El diagnóstico de fibrosis pulmonar idiopática de su ser querido se realizó mediante imágenes especializadas de los pulmones y pruebas de respiración. La palabra "idiopática" significa que la causa es desconocida. Nuestro enfoque ahora es completamente en la comodidad y el alivio de síntomas.

S03Everyone

Causes & Risk Factors

IPF pathogenesis, the "two-hit" hypothesis, modifiable and hereditary risk factors, telomere disease connections, and the clinical answer to the question every family asks: "Why did this happen?"

Modifiable & Environmental Risk Factors

Cigarette smoking: Current or former smoker in 50–70% of IPF patients; confers approximately 2-fold increased risk. Smoking cessation does not stop disease progression but reduces concurrent emphysema contribution and cardiovascular risk. The smoking history is relevant to the clinical picture but must never be used to imply blame.^[24]
Gastroesophageal reflux / microaspiration: GERD is present in 66–94% of IPF patients. Subclinical microaspiration of gastric contents is hypothesized to cause repeated alveolar epithelial injury. The causal relationship is debated, but GERD treatment is recommended in IPF guidelines. At hospice stage, GERD management for comfort and cough reduction remains appropriate.^[25]
Occupational exposures: Metal dust (steel, brass, lead), wood dust, stone dust, agricultural dust — each independently associated with IPF risk. The hospice clinician who asks about occupational history may identify an exposure that contextualizes the disease for the family and provides a frame for meaning. Occupational IPF from wood dust, metal dust, and agricultural exposure disproportionately affects working-class men in construction, farming, and manufacturing.^[26]
Viral infections: Epstein-Barr virus, cytomegalovirus, and hepatitis C virus have been associated with IPF in epidemiological studies. The causal relationship remains unproven but suggests a role for chronic viral injury in susceptible individuals.^[27]

Hereditary & Non-Modifiable Risk Factors

Age >60 years: The dominant risk factor — incidence approximately doubles with each decade over 60. IPF is fundamentally a disease of aging lungs in susceptible individuals.^[1]
Male sex: Approximately 60–70% of IPF patients are male, though the gender gap is narrowing with improved recognition of IPF in women. Women with IPF are more likely to be misdiagnosed and experience longer diagnostic delays.^[28]
MUC5B promoter variant (rs35705950): The most common genetic risk variant for IPF, present in ~35% of IPF patients vs. ~9% of controls. Paradoxically associated with better prognosis despite conferring risk.^[29]
Telomere gene mutations (TERT, TERC, RTEL1, PARN, DKC1): Telomere shortening is present in 25–35% of familial IPF and a subset of sporadic IPF. Short telomere syndromes affect not only the lung but also the liver (cryptogenic cirrhosis), bone marrow (aplastic anemia, MDS), and immune system. Post-transplant outcomes in patients with telomere mutations are worse due to bone marrow suppression from immunosuppression.^[30]
Surfactant protein gene variants: SFTPA1, SFTPA2, SFTPC, SFTPB — mutations in surfactant protein genes cause familial forms of pulmonary fibrosis, typically with earlier onset and more aggressive disease^[31]
Familial pulmonary fibrosis: Defined as IPF in two or more first-degree relatives; accounts for ~5–10% of all IPF. Autosomal dominant inheritance with variable penetrance. Adult children of familial IPF patients may benefit from genetic counseling and baseline pulmonary function testing.^[32]

The "two-hit" hypothesis: The current dominant model proposes that IPF develops through (1) genetic susceptibility combined with (2) repeated alveolar epithelial injury from recognized and unrecognized stimuli. In the genetically susceptible individual, this triggers aberrant wound-healing — excessive myofibroblast activation, collagen deposition, and progressive fibrosis instead of normal repair. There is no single cause to point to in most cases.^[33]

❤️ For Families: "Why Did This Happen?"

Families always ask this question, and it deserves a direct, compassionate answer. IPF was not caused by something your loved one did wrong. The disease represents the convergence of genetic susceptibility — often involving the protective caps on chromosomes called telomeres — and cumulative lung injury over decades of life. Most cases are not directly inherited, though genetic susceptibility plays a role. There is no single exposure, no single decision, and no preventable moment that caused this. The anger that comes with hearing "idiopathic" — a word meaning "we don't know the cause" — is legitimate. The patient who spent years being told they had COPD or asthma before the correct diagnosis was made has a right to be angry about the diagnostic delay. That anger is not a problem to solve — it is a truth to acknowledge.^[34]

⚕ Clinician Note: Genetic Counseling & Health Disparities

Genetic counseling referral: Even at hospice enrollment, genetic counseling is appropriate when familial pulmonary fibrosis or telomere gene mutations are identified or suspected. Adult children of familial IPF patients with telomere mutations should be assessed for short telomere syndrome manifestations (pulmonary, hepatic, hematologic) and considered for pulmonary surveillance. This referral can save lives in surviving family members.^[30]

Disparity note: IPF has historically been characterized as a disease of older white men. This characterization reflects both a genuine epidemiological pattern and a diagnostic bias. Women with IPF are more likely to be misdiagnosed, experience longer diagnostic delays, and less likely to be referred for transplant evaluation. Black Americans with IPF have worse survival in multiple registry studies — mechanisms include lower rates of transplant listing and transplantation, potentially different disease biology, and healthcare access disparities. The IPF patient who is a woman or who is from an underrepresented group may have experienced a longer diagnostic odyssey and less aggressive pre-hospice management.^[28]

S04ClinicianEveryone

Treatments & Procedures

Antifibrotic therapy, oxygen management, dyspnea and cough pharmacology, acute exacerbation protocols, transplant trajectory, and every disease-directed treatment the IPF patient may have received or may still be receiving at hospice enrollment.

The treatment landscape of IPF is defined by a paradox: the two approved disease-modifying therapies slow decline but do not stop it, and the most effective symptom management tool — opioids for dyspnea and cough — remains underused at every stage of the disease. The hospice clinician entering an IPF patient's care inherits both the legacy of antifibrotic therapy and the consequences of undertreated symptoms. Understanding what has been tried, what is still being taken, and what was never adequately prescribed is the foundation of the first hospice visit.^[12]^[13]

The IPF patient arriving at hospice may have traversed a treatment trajectory that includes years of antifibrotic therapy with significant GI side effects, multiple oxygen system changes as requirements escalated, pulmonary rehabilitation programs, transplant evaluation and possibly listing, and serial pulmonary function testing documenting the inexorable decline in FVC and DLCO. Some patients have experienced acute exacerbations that were treated with high-dose corticosteroids in the ICU. Some were intubated and survived. Some were listed for transplant and delisted when the disease progressed beyond the transplant window. Each of these experiences shapes the clinical and psychological landscape that the hospice team enters.^[35]

Antifibrotic Therapy — The Defining Medication Decision at Hospice Enrollment

Nintedanib (Ofev)

RCT Evidence

150 mg BID (dose reduction to 100 mg BID in ~25% due to GI toxicity)

Mechanism: Tyrosine kinase inhibitor targeting PDGFR, VEGFR, and FGFR — growth factor receptors involved in fibroblast activation and proliferation.^[12]

Evidence: INPULSIS-1 and INPULSIS-2 trials (Richeldi et al. 2014 NEJM) demonstrated 50% reduction in annual FVC decline rate versus placebo. No significant improvement in overall survival in the primary analysis. Subsequent open-label extension data suggest mortality benefit in some subgroups.^[12]

Side effects at end-stage IPF:

Diarrhea (62%): The dominant toxicity — dose reduction required in ~25%; in a frail, nutritionally depleted, dyspneic patient, nintedanib diarrhea is a comfort harm that must be explicitly reassessed
Nausea (24%): Compounding anorexia and cachexia
Elevated liver enzymes (14%): Requires monitoring if continuing at hospice
Vomiting (12%): Worsening nutritional decline

Hospice decision: If GI side effects are worsening nutritional status in a patient with IPF cachexia, discontinuation with informed patient agreement is appropriate. If side effects are manageable and the patient derives psychological benefit from active disease treatment, continuation is hospice-compatible.^[36]

Pirfenidone (Esbriet)

RCT Evidence

801 mg TID (2,403 mg/day) — titrated up over 14 days

Mechanism: Incompletely understood — anti-inflammatory, antifibrotic, and antioxidant properties. Inhibits TGF-β–stimulated collagen synthesis.^[13]

Evidence: ASCEND trial (King et al. 2014 NEJM) demonstrated 47% reduction in annual FVC decline and reduction in 6MWT distance decline. CAPACITY trials (Noble et al. 2011 Lancet) confirmed FVC benefit.^[13]^[37]

Side effects at end-stage IPF:

GI effects: Nausea (36%), diarrhea (26%), dyspepsia (19%) — contributing to the IPF cachexia syndrome
Photosensitivity rash (29%): Patient must avoid direct sun exposure and use sunscreen daily — challenging in a patient already restricted to indoor life from dyspnea
Fatigue and anorexia: Compounding the disease-related wasting that defines end-stage IPF

Hospice decision: The same framework as nintedanib — arguments for continuation include manageable side effects, psychological benefit from active treatment, and demonstrably slower FVC decline on therapy. Arguments for discontinuation include pill burden distress, GI harm to nutritional status, photosensitivity restriction, and patient desire to stop medications that will not prevent death. Document the decision with patient participation and rationale.^[36]

Critical note — PANTHER-IPF trial: The triple therapy of prednisone + azathioprine + N-acetylcysteine increased mortality and hospitalization vs. placebo (Raghu et al. 2012 NEJM). If this combination is in the current regimen, discontinue immediately.^[38]

Oxygen Therapy — The Clinical Backbone of IPF Symptom Management

Oxygen Prescribing in Advanced IPF

Resting oxygen: Prescribed when resting SpO₂ ≤88%; the flow rate maintaining SpO₂ >90% is the starting point. Home concentrator delivers reliably up to 5–6 L/min — above this, the delivery system must change to compressed gas or liquid oxygen^[21]
Exertional oxygen: The 6MWT exertional SpO₂ nadir determines the exertional requirement. A patient maintaining SpO₂ 92% at rest on 2 L/min but desaturating to 78% walking to the bathroom on the same flow requires a different exertional prescription — high-flow via non-rebreather mask or HFNC, with portable compressed gas or liquid oxygen for mobility^[20]
Nocturnal oxygen: Nocturnal desaturation is universal in advanced IPF, often worse than resting daytime desaturation due to reduced ventilatory drive during sleep. Nocturnal titration by pulse oximetry is standard. A single flow rate for all activities means inadequate titration^[39]
Comfort target: SpO₂ 88–92% at rest; SpO₂ >88% with manageable exertion. No evidence that driving SpO₂ above 95% improves outcomes or dyspnea in fibrotic lung — higher targets add equipment burden without comfort benefit

High-Flow Nasal Cannula (HFNC)

Indication: Refractory resting hypoxemia (SpO₂ <88% on maximum standard oxygen at 6–10 L/min) with significant dyspnea and distress not adequately controlled by standard oxygen and opioids^[40]
Parameters: 40–60 L/min heated humidified air with FiO₂ up to 100%
Benefits: Correction of hypoxemia beyond standard systems; reduction of work of breathing through flow-related positive airway pressure; dead space washout; improved mucociliary clearance from heated humidified air; significant patient-reported comfort improvement
Hospice considerations: Non-portable, complex equipment management; requires explicit planning for withdrawal. HFNC withdrawal in the terminal phase carries the same ethical and clinical weight as NIV withdrawal in ALS-FTD — midazolam and morphine must be at the bedside, family must be prepared, hospice nurse must be present^[41]

Dyspnea, Cough Management & Palliative Pharmacology

Opioids for Dyspnea in IPF

Low-dose oral morphine is the most evidence-supported comfort intervention for dyspnea in IPF — the same evidence base and clinical obligation as COPD.^[42]^[43]

Starting dose: Morphine IR 2.5–5 mg q4h scheduled for resting dyspnea; PRN 2.5–5 mg q1–2h for breakthrough dyspnea or severe cough paroxysms
Safety in IPF: IPF patients are typically not CO₂ retainers — their respiratory failure is type 1 (hypoxemic) not type 2 (hypercapnic). Opioid prescribing for dyspnea in IPF is even more clearly safe than in COPD^[44]
Route options: Liquid oral morphine for patients who cannot swallow tablets due to dyspnea; SQ morphine for patients who cannot use the oral route during AE-IPF
The IPF patient with severe resting dyspnea on 10–15 L/min oxygen who is not on an opioid has not received adequate comfort management

Cough Management — The Most Refractory Symptom

The chronic cough of IPF is mechanically driven by stretch and irritation of fibrotic lung tissue on peripheral cough receptors (C-fibers and Aδ-fibers). It is largely refractory to standard antitussives.^[45]

Low-dose opioids (first-line): Codeine 20–30 mg TID; morphine at dyspnea doses addresses both cough and breathlessness simultaneously^[46]
Thalidomide: Horton et al. 2012 RCT — 50–100 mg daily with significant cough reduction; REMS enrollment required; peripheral neuropathy is the primary limiting factor at hospice^[47]
Gabapentin: 300–1200 mg TID; evidence for chronic refractory cough in non-IPF populations; used empirically in IPF with variable results
High-dose PPI: Omeprazole 40 mg BID for microaspiration-triggered cough reduction^[25]
SLP cough suppression therapy: Breathing pattern retraining and laryngeal control; emerging IPF-specific evidence; available via telehealth
Rib fracture prevention: Chronic severe cough causes pathological rib fractures compounded by osteoporosis from steroid courses and age-related bone loss — manage cough aggressively, assess bone density history, treat fracture pain with scheduled opioids^[48]

Non-Pharmacological Dyspnea Interventions

Fan therapy: Trigeminal nerve stimulation — same mechanism as in COPD; prescribe formally, direct at the face, document in care plan^[49]
Anxiolytic therapy: Lorazepam SL PRN for dyspnea-anxiety crisis; mirtazapine for the combined dyspnea-anxiety-depression-cachexia cluster. The IPF-specific anxiety includes both panic of breathlessness and existential dread of advancing fibrosis
Positioning: Seated upright, legs dependent to reduce preload and diaphragmatic elevation — the patient lying flat is in the worst position for IPF respiratory mechanics
Pulmonary rehabilitation: Even at advanced stage, supervised exercise provides dyspnea reduction and quality of life benefits. At GAP III: gentle chair exercises, breathing technique instruction (diaphragmatic breathing, pursed-lip breathing), energy conservation education^[50]

Acute Exacerbation of IPF (AE-IPF) Management

AE-IPF is sudden, severe, and requires immediate decision-making. The advance discussion must occur at enrollment.^[5]^[6]

High-dose IV corticosteroids: Methylprednisolone 500–1000 mg IV × 3 days — standard hospital intervention with no RCT evidence of survival benefit; reserved for patients with goals including attempted reversal; requires hospitalization
NIV/BiPAP: May provide temporary dyspnea relief during AE-IPF in patients who have not established comfort-only directives
Invasive mechanical ventilation: Hospital mortality approaches 85–100% in most series. The clinical and ethical case against intubation in AE-IPF for a patient with established advanced IPF is among the strongest in all of respiratory medicine^[51]
Comfort-directed AE-IPF management: Oral or SQ morphine for air hunger; midazolam SQ or CSCI for refractory respiratory distress; maximum oxygen at highest available flow rate for comfort; fan therapy; family presence. The comfort plan must be executable at home within minutes to hours, not days

Lung Transplantation — The Pre-Hospice Trajectory

Candidacy: Typically age <65–70, BMI <35, no significant comorbidities excluding lung disease; evaluated using the Lung Allocation Score (LAS) system^[52]
IPF-specific transplant context: IPF is the most common ILD indication for lung transplant; median post-transplant survival ~5 years; single vs. bilateral lung transplant with varying institutional practice
The transplant near-miss: For patients who were listed but did not receive a transplant in time — delisted due to progression, organ went to someone sicker, patient too ill when the call came — the grief of this near-miss is specific and devastating. The transition from "waiting for lungs" to "waiting to die" is one of the most severe psychological transitions in palliative care^[53]
Post-transplant hospice: Patients who received a transplant and developed chronic lung allograft dysfunction (CLAD/BOS) may arrive at hospice with the grief of a transplant that extended life but ultimately failed^[54]
Clinical obligation: The hospice clinician who asks about the transplant journey — and listens to it fully — receives the most important clinical information about the patient's and family's psychological state

Pulmonary Hypertension & GERD Management

IPF-associated pulmonary hypertension (PH): Develops in 30–60% of patients from hypoxic vasoconstriction and vascular remodeling; adds right heart failure to the clinical picture; reduces median survival to ~1–2 years from PH diagnosis^[22]
PH comfort management: Oxygen is the primary treatment; furosemide for RHF edema comfort; sildenafil 20 mg TID — STEP-IPF trial showed modest dyspnea improvement in some subgroups; continue if established and providing symptom benefit^[55]
GERD management at hospice: High-dose PPI (omeprazole 40 mg BID) for comfort and cough reduction; prokinetic agents in appropriate patients; head-of-bed elevation. Cough reduced by GERD management is a direct quality of life improvement^[25]
Note: The hospice benefit does not preclude sildenafil for PH comfort if it is providing symptom benefit — this is symptom management, not disease-directed therapy in the traditional sense

S05Clinician

When Therapy Makes Sense

Evidence-based criteria for continuing comfort-directed and disease-modifying interventions in IPF at hospice enrollment. This is not about giving up or holding on — it's about reading the clinical situation correctly and ensuring every available comfort tool is deployed.

The IPF patient at hospice enrollment presents a clinical management landscape unlike most other hospice diagnoses. There are specific therapies — pharmacological, device-based, and procedural — that must be initiated, assessed, or explicitly decided upon at the first visit. The following criteria define when specific interventions are not only appropriate but clinically obligatory in IPF hospice care. The type 1 respiratory failure of IPF (hypoxemia without CO₂ retention) makes several of these interventions even safer and more clearly indicated than in COPD.^[42]^[44]

01

Opioid prescription for dyspnea at the first hospice visit: The IPF patient with resting dyspnea who is not on an opioid has not received adequate comfort management. Prescribe morphine immediate release 2.5–5 mg q4h and PRN at enrollment. The type 1 respiratory failure of IPF (hypoxemia without CO₂ retention) makes opioid prescribing for dyspnea even safer from a respiratory depression standpoint than in COPD — there is no CO₂ retention to blunt the respiratory drive further. Titrate at every visit. The patient who is dyspneic at rest on the current dose needs a dose increase. Document the evidence basis at every visit.^[42]^[43]
02

Opioids for cough at the same time as opioids for dyspnea: Morphine or codeine for IPF cough simultaneously addresses both symptoms through related but distinct mechanisms — central cough suppression and dyspnea perception modulation. Codeine 20–30 mg TID as a starting cough dose for the cough-predominant patient. The combined dyspnea and cough management with a single opioid simplifies the medication regimen and addresses both central comfort problems simultaneously. Prescribe together, not sequentially, not on different visits.^[46]
03

Fan therapy prescribed formally and documented in the care plan: Trigeminal nerve stimulation via directed facial airflow reduces the subjective sensation of breathlessness through a mechanism independent of oxygenation. This costs nothing, has no side effects, and provides measurable comfort benefit. A handheld or bedside fan directed at the patient's face should be prescribed and documented as a formal comfort intervention at enrollment.^[49]
04

Oxygen titration assessment at enrollment — three separate prescriptions: Determine whether the current oxygen prescription is adequate for rest, exertion, and sleep separately. The patient whose resting prescription is 4 L/min and whose exertional prescription has never been separately assessed has an incomplete oxygen management plan. If the resting flow rate exceeds 5–6 L/min, assess whether the current delivery system (concentrator) can meet the demand — if not, arrange compressed gas cylinders, liquid oxygen, or HFNC evaluation. Document all three oxygen prescriptions in the plan of care.^[21]^[20]
05

Antifibrotic reassessment at enrollment: Explicit discussion of continuation versus discontinuation with the patient. If side effects are manageable and the patient derives benefit — physiological or psychological — continuation is hospice-compatible and appropriate. If GI side effects are harming nutritional status, discontinuation with informed agreement is equally appropriate. Document the decision and rationale. If continuing, monitor GI side effects actively and adjust dose if necessary.^[36]
06

GERD and microaspiration management: High-dose PPI (omeprazole 40 mg BID or equivalent) for comfort and cough reduction. Prokinetic agents in appropriate patients. Head-of-bed elevation documented in care plan. The cough that is reduced by GERD management is a direct improvement in quality of life. Even though the disease-modification rationale for GERD treatment is moot at hospice stage, the comfort rationale — reduced cough, reduced microaspiration events, reduced esophageal discomfort — remains strong.^[25]
07

IPF-associated pulmonary hypertension management for comfort: Oxygen is the primary treatment. Furosemide for right heart failure edema comfort. Sildenafil 20 mg TID has been studied in IPF-PH with modest benefit in some subgroups (STEP-IPF trial) and may be continued if established and providing symptom benefit. The hospice benefit does not preclude sildenafil for PH comfort — this is symptom management.^[55]
08

Rib fracture pain management with scheduled analgesics including opioids: Rib fractures from chronic cough in osteoporotic IPF patients require active analgesic management. The patient with a known rib fracture not on scheduled analgesia is experiencing preventable pain. Chest wall pain from rib fractures worsens dyspnea through splinting — treating the pain relieves both the pain and the breathing difficulty. Assess for fractures at every visit in patients with severe cough.^[48]
09

AE-IPF advance planning documented at enrollment: Specific decision framework for what to do when acute respiratory worsening occurs. Does the patient want high-dose IV steroids attempted (requiring hospitalization) or comfort-only management at home? This decision must be documented in the advance directive and POLST before the event occurs. The midazolam and morphine for AE-IPF comfort must be prescribed and in the home before the first exacerbation.^[5]^[51]
10

Genetic counseling for familial IPF or telomere disease presentations: Adult children of familial IPF patients or patients with telomere gene mutations benefit from early surveillance and genetic counseling referral. This referral has direct implications for surviving family members — short telomere syndromes affect lung, liver, bone marrow, and immune system. The genetic counseling referral at hospice enrollment can save lives in the next generation.^[30]
11

Caregiver training on oxygen equipment management: The IPF home is often a complex oxygen environment with concentrators, cylinders, and possibly HFNC. The caregiver who does not understand the equipment cannot manage the comfort plan effectively. Equipment training at enrollment is a clinical priority — how to switch between oxygen sources, how to troubleshoot concentrator failure, how to assess when flow rate is inadequate, and when to call the hospice nurse versus the equipment company.

S06Clinician

When It Doesn't

Knowing when treatment stops helping is not clinical failure. It is the most important clinical skill in IPF. These are the interventions that cause net harm at the end-stage of this disease.

IPF hospice care is defined as much by what is not done as by what is done. The interventions below — invasive ventilation, high-dose IV steroids in comfort-only patients, antifibrotic continuation through GI devastation, unnecessary hospitalization — represent the most common sources of preventable suffering in end-stage IPF. The hospice clinician's role is to protect the patient from these harms while ensuring that every available comfort intervention is maximized. The advance directive and POLST must be constructed specifically to prevent inadvertent escalation during acute events.^[51]^[56]

01

Invasive mechanical ventilation for AE-IPF in a patient with established advanced IPF and comfort-aligned goals: The in-hospital mortality of invasive mechanical ventilation for AE-IPF exceeds 85–100% in most published series. The patient who survives to ICU discharge from AE-IPF intubation rarely returns to their pre-exacerbation functional baseline. The ventilator becomes a bridge to nowhere in almost every case. The advance directive must specifically prohibit invasive mechanical ventilation in AE-IPF by name, with clear explanation to the family that this is not a withholding of beneficial treatment — it is a protection from prolonged, futile, and suffering-producing ICU care.^[51]^[6]
02

High-dose IV corticosteroids for AE-IPF in a comfort-only patient: IV methylprednisolone 500–1000 mg is the standard intervention attempted for AE-IPF in hospitalized patients with goals that include attempting reversal. In a comfort-only hospice patient, this treatment requires hospitalization, IV access, monitoring, and carries significant side effects (hyperglycemia, infection risk, psychiatric effects) with uncertain and generally poor benefit. The comfort-only AE-IPF is managed with morphine, midazolam, and maximum oxygen comfort at home. The IPF patient who goes to the hospital during an AE-IPF is at risk of involuntary escalation to intubation by an ED or ICU team that does not know their advance directive. The advance directive and POLST must be immediately accessible in the home and carried on the patient at all times.^[57]
03

Antifibrotic continuation when GI side effects are causing significant harm to nutritional status and quality of life: Nintedanib diarrhea and pirfenidone nausea in an already malnourished, frail, dyspneic IPF patient are not trivial. If the patient is losing weight that they cannot afford to lose, vomiting multiple times daily, or spending significant time managing GI symptoms, the antifibrotic is causing net harm. Discontinue after discussion with the patient. The decision to stop antifibrotic therapy is not giving up — it is redirecting clinical energy from disease modification that is no longer modifying the trajectory meaningfully to comfort that is immediately measurable.^[36]
04

Hospitalization for routine oxygen management issues or equipment failures: Oxygen concentrator failure, cylinder supply issues, mask fit problems — all should be managed by home oxygen supplier and hospice equipment management without hospital admission. The IPF patient who goes to the ED for an oxygen equipment issue has entered the highest-risk environment for inadvertent escalation — an ED team unfamiliar with the advance directive, unfamiliar with comfort-focused IPF management, and trained to intubate respiratory failure. Home oxygen troubleshooting must be part of the hospice plan of care from day one.
05

Immunosuppression therapy for IPF: The PANTHER-IPF trial (Raghu et al. 2012 NEJM) demonstrated that the triple therapy of prednisone + azathioprine + N-acetylcysteine increased mortality and hospitalization compared to placebo. This combination must not be used for IPF. If it is in the current regimen for any reason — sometimes carried forward from an era before the trial or from a misdiagnosis — reassess and discontinue immediately with documentation of the rationale.^[38]
06

High-dose continuous oxygen above the patient's established comfort requirement: There is no evidence that driving SpO₂ above 95% in a fibrotic lung improves outcomes or dyspnea. The comfort oxygen target of SpO₂ 88–92% for resting and SpO₂ >88% with manageable exertion balances equipment burden against physiological need. Driving SpO₂ higher adds equipment burden, noise, nasal dryness, and restriction of mobility without comfort benefit.
07

IPF-specific pulmonary rehabilitation in a patient whose dyspnea and hypoxemia make exertion too distressing: Rehabilitation must be calibrated to functional reserve. In a patient desaturating to 78% with any exertion on maximum available oxygen, formal exercise programs cause distress without benefit. The rehabilitation at this stage is breathing technique, energy conservation, and chair-based activity — not structured exercise.^[50]
08

Diagnostic bronchoscopy, CT scanning, or invasive procedures for routine monitoring: Once the hospice diagnosis is established and the trajectory is terminal, serial HRCT scans and bronchoscopy do not change management and add procedural burden, radiation exposure, sedation risk, and transportation distress. Reassess all scheduled investigations at enrollment and cancel those that cannot alter the clinical comfort plan. The only imaging that changes management at this stage is imaging to evaluate a new symptom that may have a treatable cause (e.g., pneumothorax, large pleural effusion).

📋 Clinician Note: Preventing Inadvertent Escalation

The greatest single risk to the comfort-focused IPF patient is inadvertent escalation during an acute event. AE-IPF causes sudden, severe respiratory distress that panics families. A family in panic calls 911. Paramedics intubate. The ED team does not have the advance directive. The patient is on a ventilator in an ICU within hours of an event that had a documented plan for comfort management at home. The prevention of this scenario is one of the most important clinical acts in IPF hospice: the advance directive must be visible in the home, the POLST must be on the refrigerator, the family must understand — before the event — that calling the hospice nurse first is the correct response, and the comfort medications must be in the home and accessible before the first exacerbation arrives.^[56]

S07Everyone

Out-of-the-Box Approaches

Evidence-graded integrative, interventional, and complementary approaches for IPF symptom management at hospice. Grade A = RCT / guideline-level; B = multi-observational / strong clinical; C = limited clinical with strong rationale; D = expert opinion / case series.

Low-Dose Opioids for IPF Cough & Dyspnea Simultaneously — The Dual-Target Prescription

Grade B

Codeine 20–30 mg TID (cough-predominant) · Morphine IR 2.5–5 mg q4h (cough + resting dyspnea)

The chronic refractory cough of IPF and the dyspnea of advanced fibrosis are two of the three central comfort problems at end stage. Low-dose opioids address both through distinct but complementary mechanisms — central cough suppression via opioid receptors in the medullary cough center and dyspnea reduction via opioid receptor activity in the respiratory perception centers.^[46]

The clinical efficiency of addressing both with a single medication simplifies the regimen and provides the most evidence-supported treatment for both symptoms simultaneously. The OPTion trial (Verberkt et al. 2021) and multiple observational studies support opioid cough suppression in IPF specifically.^[58] Codeine 20–30 mg TID for the cough-predominant patient not yet severely dyspneic at rest; low-dose morphine 2.5–5 mg q4h for the patient with both significant cough and resting dyspnea.

Clinical imperative: Prescribe opioids for cough at the same visit as opioids for dyspnea — not sequentially, not on different visits, but together as a single comprehensive comfort decision. The type 1 respiratory failure of IPF makes this even safer than in COPD.^[44]

Thalidomide for Refractory IPF Cough

Grade B

Thalidomide 50–100 mg daily at bedtime · REMS enrollment (STEPS program) required

The Horton et al. 2012 Annals of Internal Medicine double-blind crossover RCT demonstrated significant reduction in cough severity scores with thalidomide 50–100 mg daily versus placebo in IPF patients. The effect size was clinically meaningful.^[47]

Side effects in the IPF hospice population:

Peripheral neuropathy: Additive to any existing neuropathy from diabetes or other causes — the primary limiting factor at hospice
Sedation: Potentially useful if cough is disrupting sleep
Constipation: Adds to opioid-related constipation burden — requires proactive bowel management
DVT risk: Significant in an immobile, hypercoagulable fibrosis patient — requires VTE prophylaxis assessment

At hospice stage in an elderly patient without childbearing potential, the teratogenicity risk is not the primary concern. In a patient whose cough is causing rib fractures, sleep deprivation, and urinary incontinence despite optimized opioid and gabapentin therapy, thalidomide at 50 mg nightly represents a clinically justified escalation.

Gabapentin for Refractory IPF Cough as Adjunct

Grade C

300 mg TID → titrate to 900–2,400 mg/day · Renal dose adjustment required

The mechanistic rationale is inhibition of peripheral sensory nerve sensitization (C-fiber hypersensitivity) that drives the chronic cough reflex in IPF. Evidence in non-IPF chronic refractory cough is stronger than IPF-specific data. In practice, gabapentin is commonly used in IPF cough management when opioids alone are insufficient.^[59]

The sedation side effect is potentially useful for sleep and anxiety management. The primary risk is additive sedation with opioids requiring careful monitoring. Renally dose-adjusted in patients with impaired renal function from cor pulmonale–related low cardiac output. Document the cough indication explicitly in the medication plan and reassess at every visit for sedation burden.

High-Flow Nasal Cannula (HFNC) for Refractory Hypoxemia — The Comfort Indication

Grade C

40–60 L/min heated humidified air · FiO₂ 40–100% · Non-portable home unit

HFNC provides multiple physiological benefits in advanced IPF: correction of hypoxemia beyond standard oxygen systems; reduction of work of breathing through flow-related positive airway pressure; reduction of anatomical dead space by continuous nasopharyngeal washout; improvement in mucociliary clearance from heated humidified air; patient-reported dyspnea and comfort improvement in multiple observational studies.^[40]

Hospice indication: Refractory resting hypoxemia (SpO₂ <88% on maximum standard oxygen at 6–10 L/min) with significant dyspnea not adequately controlled by standard oxygen and opioids. Requires a specific prescription, specialized equipment (non-portable), patient tolerance of high-flow nasal cannula, and explicit planning for withdrawal.

Critical planning: When HFNC is discontinued in the terminal phase, respiratory distress precipitates rapidly. The HFNC withdrawal protocol must parallel the NIV withdrawal protocol in ALS-FTD: midazolam and morphine at the bedside, family preparation, hospice presence.^[41]

SLP Cough Suppression Therapy — Laryngeal Control & Breathing Retraining

Grade C

Telehealth or in-person SLP sessions · 4–8 sessions typical · Cough severity score threshold: LCQ >40/100

Speech-language pathologist–delivered cough suppression therapy for IPF-associated chronic refractory cough is an emerging intervention with growing evidence in chronic refractory cough populations broadly and limited but promising IPF-specific data.^[60]

Techniques: Breathing pattern retraining (replacing cough reflex initiation with controlled breathing patterns); laryngeal control training (voluntarily inhibiting the laryngeal adduction response that initiates the cough); psychoeducational components addressing cough self-management.

Available via telehealth in some SLP practices with ILD expertise. The referral is appropriate in any IPF hospice patient with significant cough burden. The SLP who specializes in chronic refractory cough can address the behavioral component of cough hypersensitivity that pharmacological agents cannot — making this a genuinely complementary approach to opioid and gabapentin therapy. Telehealth delivery makes it accessible to homebound patients.

Sildenafil for IPF-Associated Pulmonary Hypertension — The STEP-IPF Legacy

Grade C

Sildenafil 20 mg TID

The STEP-IPF trial (Han et al. 2013 AJRCCM) of sildenafil vs. placebo in IPF patients with DLCO <35% predicted showed no improvement in the primary endpoint (6MWT distance at 12 weeks) but demonstrated significant improvement in secondary endpoints including dyspnea scores, quality of life, and gas exchange.^[55]

If a patient was already on sildenafil before hospice enrollment and reports dyspnea benefit or right heart failure symptom improvement, continuation is appropriate and hospice-compatible. The decision to initiate sildenafil in a newly enrolled hospice patient with IPF-PH must weigh the potential comfort benefit against the complexity of adding a medication at a stage when medication rationalization is often the priority. Discuss with the attending pulmonologist. Sildenafil for PH comfort is symptom management, not disease-directed therapy in the traditional sense.

Mirtazapine for the Dyspnea-Anxiety-Depression-Cachexia Cluster

Grade C

Mirtazapine 7.5–15 mg at bedtime · Titrate to 30 mg as tolerated

Mirtazapine addresses multiple overlapping symptoms common in end-stage IPF through a single medication: appetite stimulation and weight gain (via H₁ receptor antagonism) counteracting IPF cachexia; anxiolytic properties reducing the dyspnea-anxiety cycle; sedation at lower doses improving sleep disrupted by nocturnal cough and hypoxemia; emerging evidence for dyspnea perception modulation in ILD.^[61]

The IPF patient with the combined burden of anxiety, depression, anorexia, insomnia, and dyspnea is an ideal candidate for mirtazapine. The sedation that limits its use in active patients is a benefit in a patient whose sleep is destroyed by cough, anxiety, and nocturnal desaturation. Start at 7.5 mg nightly; lower doses are more sedating, higher doses less so.

AE-IPF Advance Directive — The Single Most Important Clinical Act

Grade A

Complete at first hospice visit · Review at every subsequent visit · POLST on refrigerator

The acute exacerbation of IPF can kill within 24–72 hours of onset. The family who has not discussed and documented the AE-IPF management plan before the event occurs will be making life-and-death decisions in a state of panic with a team they may have never met.^[56]

The advance directive in IPF must specifically document:

(1) Whether the patient wants attempted treatment of AE-IPF with high-dose IV corticosteroids (requiring hospitalization)
(2) Whether the patient accepts noninvasive ventilation (BiPAP or HFNC) as a comfort measure during AE-IPF
(3) Whether the patient categorically refuses invasive mechanical ventilation — with explicit understanding that survival from AE-IPF intubation is <15% in most published series and that those who survive rarely return to their pre-AE baseline^[51]
(4) Whether the patient's preference is to remain at home during AE-IPF with comfort-only management

Document these four decisions explicitly, review them with the family, include them in the POLST, post the POLST visibly in the home, and review at every hospice visit to ensure they remain current. This is not a bureaucratic exercise — it is the single most important act of patient safety in IPF hospice care.

S08Everyone

Natural & Herbal Options

Evidence grading, dosing where supported, drug interaction flags, and explicit contraindications specific to IPF. Patients will use supplements — this section helps you have the right conversation.

⚠ IPF-Specific Supplement Safety — Four Constraints

IPF creates a supplement safety landscape with four specific clinical constraints that do not apply to most other hospice diagnoses:^[42]

(1) Respiratory irritant sensitivity — the fibrotic lung parenchyma is exquisitely sensitive to any inhaled irritant. No supplement should be inhaled, diffused, or used in steam inhalation that could cause airway inflammation or bronchospasm.^[43]
(2) Cough amplification risk — several supplements cause GI effects that increase the likelihood of microaspiration events that trigger coughing in an already cough-sensitized patient.^[44]
(3) Antifibrotic drug interactions — nintedanib is metabolized by esterases and minimally by CYP3A4; strong CYP3A4 inhibitors or inducers affect nintedanib levels. Pirfenidone is metabolized by CYP1A2 and CYP2C9; CYP1A2 inhibitors (fluvoxamine, some herbal preparations) increase pirfenidone exposure significantly.^[18]
(4) VTE risk amplification — IPF patients have elevated baseline VTE risk from inflammation, immobility, and fibrosis. Any supplement with procoagulant properties adds to this risk in an already vulnerable population.^[45]

The fundamental principle: no supplement should be added to the IPF regimen without explicit evaluation of all four constraints. Most supplements add complexity, potential harm, and patient burden without meaningful comfort benefit in advanced IPF. The clinical energy should go toward optimizing opioids, oxygen, cough management, and caregiver support — not supplement trials.

Herb / Supplement	Evidence Grade	Typical Dose	Potential Benefit	⚠ Interactions / Contraindications
Melatonin	Grade C	3–5 mg PO at bedtime	Sleep disruption from nocturnal cough and nocturnal hypoxemia. Sleep in advanced IPF is severely disrupted by cough episodes, nocturnal desaturation causing arousal, anxiety, and rib fracture pain. Patients who sleep more deeply have fewer nocturnal cough arousal events. Lowest-risk sleep intervention available in IPF.^[46]	No significant interaction with nintedanib or pirfenidone. No bronchoconstrictive or airway irritant properties. Does not amplify cough. Does not affect VTE risk. Safe in combination with opioids and benzodiazepines — monitor for additive sedation.
Honey (medical-grade or standard)	Grade C	1 teaspoon (5 mL) at bedtime	Nocturnal cough — demulcent properties coat pharyngeal mucosa reducing afferent cough receptor stimulation. The oldest and simplest anti-cough demulcent with genuine mechanistic rationale. The family who wants to do something concrete for the cough at bedtime can be directed to honey without safety concern.^[47]	No airway irritant properties. No interaction with antifibrotic medications. No amplification of cough reflex. No VTE risk contribution. Safe at food amounts in all IPF patients. Avoid in patients with uncontrolled diabetes — monitor blood glucose.
Ginger	Grade B	250–500 mg PO BID	Antifibrotic GI side effects — nausea and GI irritation from nintedanib and pirfenidone are the primary reasons for dose reduction and discontinuation. Evidence for nausea reduction from chemotherapy-related nausea trials applicable to antifibrotic GI burden. One of the safest comfort adjuncts for GI symptom management in IPF.^[48]	No significant interaction with nintedanib (esterase metabolism) or pirfenidone (CYP1A2/2C9) at standard supplement doses. No airway irritant properties. No VTE risk amplification at recommended doses. Mild antiplatelet effect at very high doses (>4 g/day) — avoid exceeding 1 g/day total.
N-Acetylcysteine (NAC) — as mucolytic only	Grade C	200–400 mg PO TID (mucolytic dose)	Sputum viscosity reduction and cough reduction from mucus retention. NOT for disease modification — PANTHER-IPF showed no disease modification benefit. Low-dose NAC as mucolytic is a different application than the 600 mg TID disease-modification dose. If sputum retention contributes to cough severity, reasonable comfort adjunct.^[27]	No interaction with nintedanib or pirfenidone at mucolytic doses. No airway irritant properties at oral doses. Document indication as comfort (mucolytic), NOT disease modification. ⚠ Do not confuse with PANTHER-IPF triple therapy protocol.

🚫 Avoid in IPF

Eucalyptus oil & menthol inhalation/steam diffusion: The fibrotic lung parenchyma and sensitized airway cough receptors in IPF are acutely sensitive to inhaled volatile organic compounds including eucalyptus cineole and menthol. Inhalation can trigger acute bronchospasm and severe coughing paroxysms that are life-threatening in a patient with no pulmonary reserve. The family using a eucalyptus or menthol diffuser "to help the breathing" must be told immediately and specifically that this is potentially dangerous in IPF. Remove from the home environment.^[43]
St. John's Wort: CYP3A4 inducer — reduces nintedanib blood levels by inducing CYP3A4-mediated metabolism. Also a CYP1A2 inducer which reduces pirfenidone exposure. In either case, SJW undermines antifibrotic therapy. Absolutely contraindicated in any IPF patient on antifibrotic therapy. Also contraindicated in combination with opioids for which it may alter metabolism unpredictably.^[18]
High-dose fish oil (>3 g/day): Antiplatelet and mild anticoagulant properties — VTE is already elevated risk in IPF from immobility and inflammation. At high doses, omega-3 supplements cause GI side effects that worsen antifibrotic GI burden and may trigger cough through microaspiration. Low doses (1 g daily) are acceptable if already in use.^[45]
Ginkgo biloba: Antiplatelet effect adds to VTE risk — ginkgo has both antiplatelet and potentially procoagulant properties in various studies. The net VTE effect is uncertain. No evidence for benefit in IPF. No benefit for cough or dyspnea. Discontinue if present in the regimen.
High-dose antioxidants (Vitamin C >2 g/day, Vitamin E >400 IU, beta-carotene): The antioxidant strategy for IPF has been extensively studied and has not demonstrated clinical benefit. High-dose vitamin E >400 IU increases all-cause mortality in meta-analysis. Beta-carotene in smokers and former smokers — a population heavily represented in IPF — is associated with increased lung cancer risk. Remove from the regimen.^[27]
Any supplement marketed as "reversing lung fibrosis," "dissolving scar tissue," "regenerating alveoli," or "stopping IPF progression" without peer-reviewed RCT evidence specifically in IPF. The IPF supplement market exploits the desperation of patients told that nothing can stop the disease. Address this directly and compassionately: "I want to protect you from spending money and energy on products that have not been tested in IPF — the research community has been looking for something that can reverse fibrosis for decades and has not found it in any supplement. The energy you have is precious and I would rather it go toward the time and comfort that you have."

From the Field

Waldo Rios, NP

Hospice NP · 12+ Years

"In IPF, the supplement conversation is different from cancer. The IPF patient isn't usually chasing a cure supplement — they're watching the eucalyptus diffuser their daughter bought running in the corner of the living room, or they're taking high-dose fish oil because someone at pulmonary rehab recommended it two years ago and nobody re-evaluated it. The conversation here is not 'what are you hoping supplements will do?' — it's 'let me check that everything in your house and in your medicine cabinet is safe for the specific kind of lungs you have now.' Say it that way. They'll open the cabinet for you."

— Waldo, NP · Terminal2

S09Everyone

Timeline Guide

A guide, not a prediction. IPF's trajectory is among the least predictable in all of respiratory medicine — extended plateaus, relentless decline, and sudden catastrophic exacerbations all occur, sometimes in the same patient.

The IPF timeline is uniquely characterized by its unpredictability. The disease may be slow and punctuated by extended periods of stability, or it may be relentlessly progressive without plateau. The acute exacerbation of IPF (AE-IPF) that kills within days arrives without warning at any stage of either trajectory. The hospice clinician must prepare families for both the possibility of an extended terminal phase and the possibility of a sudden catastrophic event that compresses the entire remaining trajectory into days. The timeline must also acknowledge the transplant journey that preceded hospice enrollment for many patients — the years of evaluation, listing, and waiting that shaped the family's entire experience of IPF before hospice was considered.^[1]^[3]

YRS

The Diagnostic Odyssey & Pre-Hospice Years

Presentation: IPF typically presents as progressive exertional dyspnea and dry cough in a patient in their 60s. The initial evaluation may produce diagnoses of COPD, heart failure, asthma, or hypersensitivity pneumonitis. The diagnostic delay averages 2–3 years.^[6]
Diagnosis confirmed: By the time the correct diagnosis of IPF is made, the FVC has often declined by 10–20% from its earliest abnormal value. The antifibrotic medications (nintedanib or pirfenidone) are started — with hope and with side effects — and the patient and family adjust to the reality of a disease that will not stop.^[15]^[16]
Rehabilitation and transplant: Pulmonary rehabilitation may be undertaken. The transplant evaluation begins if the patient is an appropriate candidate (typically age <65–70, BMI <35, no significant comorbidities). The years on the transplant list — with periodic assessments, priority score adjustments, false alarms, and the knowledge that the lungs are still declining while waiting — are among the most psychologically demanding years of any hospice patient's pre-enrollment life.^[63]
Hospice relevance: The clinician who asks about the transplant journey and listens to it receives the most important contextual information of the enrollment. This history shapes every subsequent clinical and psychosocial interaction.

MOS

Progressive Decline — Approaching Hospice Eligibility

Physiological decline: FVC declining to <70% predicted; DLCO declining to <40% predicted; exertional hypoxemia severe enough to require supplemental oxygen; 6MWT distance declining. GAP Stage III reached — median survival 1.4 years from this point.^[2]
Oxygen escalation: Resting oxygen added, then nocturnal oxygen. Activity-limiting dyspnea becomes the defining daily experience. The oxygen prescription that was adequate three months ago no longer covers exertion.
Transplant decision: The transplant evaluation may conclude that the patient is no longer a candidate (too ill for surgery, comorbidities developing, DLCO too low) or the patient may be delisted. The decision to enroll in hospice may coincide with the decision to delist from transplant.^[64]
Critical planning: Advance care planning conversations must be initiated in this phase. The AE-IPF management preferences must be documented before the first acute exacerbation. Antifibrotic continuation decision made explicitly.^[71]

WKS

Active Terminal Decline — Hospice Active Phase

Oxygen escalation continues: Oxygen requirement escalating; dyspnea at rest established; the current delivery system may be inadequate. HFNC considered if available and indicated.^[33]
Cough crisis: Cough severe and potentially causing rib fractures. Weight loss from cachexia and from cough effort. Functional capacity severely limited — unable to walk beyond a few steps without severe desaturation.^[39]
Pulmonary hypertension: IPF-associated pulmonary hypertension clinically evident if present — peripheral edema, hepatomegaly, elevated JVP. Right heart failure management for comfort.^[56]
AE-IPF risk ever-present: Acute exacerbation possible at any point in this phase. If managed at home with comfort medications, the trajectory to death may be within days to weeks. If the patient appears to recover, a period of stability at a lower functional baseline may follow before the next episode.^[49]
Clinical priorities: Opioid titration ongoing; cough management optimization; caregiver oxygen management training; family preparation for AE-IPF crisis protocol.

DAYS

Terminal Phase — Respiratory Failure or AE-IPF

AE-IPF presentation: Acute worsening of dyspnea over hours to days with bilateral ground-glass opacities superimposed on established fibrosis — OR progressive respiratory failure without acute exacerbation. Per-episode in-hospital mortality of AE-IPF is 50–80%.^[49]^[50]
Oxygen failure: SpO₂ no longer maintainable above 88% even on maximum available oxygen. Increasing air hunger. The gap between oxygen supply and tissue demand is closing irrevocably.
Comfort medications around the clock: Morphine for dyspnea and air hunger; midazolam for agitation and anxiety; glycopyrrolate for secretions. The decision regarding HFNC or NIV continuation or withdrawal must be executed according to the advance directive.^[30]
Family preparation: The family who has been prepared for what respiratory failure in IPF looks like — the air hunger, the increasing breathing effort, and then the transition — is not ambushed by what they see.

HRS

Final Hours

Terminal event: The terminal event in IPF is typically hypoxemic respiratory failure. SpO₂ falls below 80% despite maximum oxygen. Breathing becomes increasingly labored and then slows.^[71]
CO₂ narcosis: In CO₂-retaining patients, hypercapnic coma may produce a relatively peaceful transition. In the hypoxemic-predominant IPF patient, air hunger may be severe until adequate opioid and midazolam sedation provides comfort.
Active management: Morphine SQ continuous or PRN every 15–30 minutes for air hunger; midazolam SQ for agitation; glycopyrrolate for secretions; fan directed at face; upright positioning as tolerated.
The prepared family: The hospice clinician who prepared the family for this transition — who specifically told them that air hunger will be managed with morphine and midazolam and that these medications are the most merciful clinical act available — has provided a gift that cannot be given after the fact.^[73]

S10Clinician

Medications to Anticipate

Symptom-targeted pharmacology for IPF. What to have in the comfort kit, what to titrate first, and what the evidence supports for every symptom domain.

🚨 CRITICAL NOTE — Three Non-Negotiable Priorities at the First Visit

IPF medication management at hospice enrollment has three non-negotiable clinical priorities that must all be completed at the first visit:^[28]^[30]

(1) Opioid initiation for dyspnea AND cough — morphine or codeine prescribed, dispensed, and reviewed with the patient and family before the visit ends. The combined dyspnea and cough burden of end-stage IPF is the central suffering of this disease and opioids address both simultaneously.
(2) AE-IPF emergency comfort protocol — the medications and the documented plan for an acute exacerbation must be in the home before the exacerbation occurs, because AE-IPF may kill within 24–72 hours and there is no time for prescription processing during the event.
(3) Antifibrotic medication reassessment — the decision to continue or discontinue antifibrotic therapy must be made explicitly at enrollment with the patient's participation, documented with rationale, and communicated to all members of the care team.

These three priorities completed at the first visit define the standard of care for IPF hospice.

Drug	Class / Target Symptom	Starting Dose	Notes / Cautions
Morphine IR	Opioid / Dyspnea at rest + Cough	2.5–5 mg PO q4h scheduled + 2.5–5 mg q1–2h PRN	First-line for both resting dyspnea and cough — document BOTH as dual indications. IPF is type 1 respiratory failure (no CO₂ retention) — titrate more aggressively than COPD with CO₂ retention. Liquid oral morphine for patients who cannot swallow tablets due to dyspnea. SQ morphine for patients who cannot use the oral route during AE-IPF. Titrate at every visit.^[28]^[29]^[30]
Codeine	Opioid antitussive / Cough-predominant IPF	20–30 mg PO TID	First-line antitussive opioid for cough-predominant patients not yet severely dyspneic at rest. Most evidence-supported antitussive for IPF cough (OPTion trial). When dyspnea at rest also present, transition to morphine which addresses both. ⚠ Do not use in poor CYP2D6 metabolizers — prodrug requiring CYP2D6 metabolism to active morphine. Ultra-rapid metabolizers may experience excessive opioid effect.^[37]
Fan therapy	Non-pharmacological / Dyspnea	Handheld or bedside fan directed at face — continuous during dyspnea episodes	Prescribe formally and document in the care plan. Trigeminal nerve (V2 distribution) stimulation reduces central perception of dyspnea. RCT-supported (Galbraith 2010). No side effects. No drug interactions. Must be positioned correctly — airflow across nasal/oral area, not body. Prescribe at enrollment alongside opioids.^[31]
Supplemental O₂	Oxygen / Hypoxemia	Titrate to SpO₂ ≥88%; separate prescriptions for rest, exertion, and sleep	The oxygen prescription that covers rest does NOT cover exertion in IPF. Assess exertional SpO₂ at the first visit — 5 steps of ambulation with pulse oximetry. If resting flow >5–6 L/min, assess whether current delivery system meets demand. Document rest, exertional, and sleep prescriptions separately. Consider HFNC if standard nasal cannula insufficient.^[32]^[33]
Nintedanib	Antifibrotic / Disease modification	150 mg PO BID (or dose-reduced 100 mg BID)	Continuation or discontinuation decision documented at enrollment. If continuing: monitor diarrhea, nausea, elevated LFTs; loperamide for diarrhea management; dose reduce to 100 mg BID if GI side effects affect QOL significantly. The antifibrotic causing net harm through GI side effects in a nutritionally depleted patient should be discontinued after discussion.^[15]^[20]
Pirfenidone	Antifibrotic / Disease modification	801 mg PO TID (2403 mg/day)	Continuation or discontinuation decision documented at enrollment. If continuing: monitor nausea, photosensitivity (strict sun avoidance + sunscreen), anorexia contributing to IPF cachexia. Dose reduce if GI burden worsening nutritional status. ⚠ CYP1A2 substrate — fluvoxamine and CYP1A2 inhibitors increase exposure significantly.^[16]^[17]
Omeprazole (or equivalent PPI)	PPI / GERD, microaspiration, cough reduction	40 mg PO BID	High-dose PPI for GERD and microaspiration management — reduces microaspiration frequency and may reduce cough trigger events. Also provides GI protection for patients on NSAIDs or steroids. Continue at hospice enrollment for cough comfort indication.^[66]
Gabapentin	Gabapentinoid / Refractory cough adjunct	300 mg PO TID, titrate to 900–1800 mg/day	For cough not adequately controlled by opioid alone. Sensory nerve sensitization in IPF cough responds partially to gabapentinoids through different mechanism than opioid cough suppression. Additive benefit when combined with opioid antitussives. Monitor for additive sedation with opioids. Renally dose-adjusted. Document cough indication explicitly.^[38]
Thalidomide	Immunomodulator / Refractory IPF cough	50 mg PO at bedtime	For refractory IPF cough unresponsive to opioids and gabapentin. Horton et al. 2012 RCT demonstrated significant cough reduction. Requires REMS STEPS program enrollment. ⚠ Peripheral neuropathy, DVT risk (significant in immobile IPF patient), constipation (adds to opioid burden), sedation (useful for nocturnal cough). Explicit informed consent required. Bowel management protocol essential.^[36]
Lorazepam	Benzodiazepine / Anxiety-dyspnea crisis	0.5–1 mg SL PRN	For panic that accompanies severe dyspnea in IPF. Sublingual onset faster than oral for acute crisis. Must be in the home from day one. Dual-medication crisis protocol: morphine for air hunger + lorazepam for panic. Limited evidence for dyspnea alone — primary indication is the anxiety component.^[35]
Midazolam	Benzodiazepine / AE-IPF comfort, terminal agitation	5–10 mg SQ PRN; CSCI 10–30 mg/24h for refractory dyspnea	The single most important medication for AE-IPF comfort management at home. Must be prescribed, drawn, labeled, and accessible in the home BEFORE the first AE-IPF event. The family must know where it is and the hospice nurse must have reviewed its administration. When AE-IPF begins, time to comfortable sedation is measured in minutes — the midazolam that is not in the house cannot be given.^[49]^[50]
Glycopyrrolate	Anticholinergic / Terminal secretions	0.2 mg SQ q4h	Reduces secretions without CNS effects. Preferred over hyoscine in conscious patients. Critical in terminal phase of respiratory failure. Also reduces secretion volume that triggers cough paroxysms. Alternative: scopolamine 1.5 mg transdermal patch q72h.^[30]
Dexamethasone	Corticosteroid / AE-IPF, inflammation	4–8 mg PO/SQ daily for AE-IPF; taper per clinical response	For AE-IPF in patients with goals that include attempting stabilization. Evidence for steroid benefit in AE-IPF is limited and no RCT exists. In comfort-only hospice: may provide short-term anti-inflammatory benefit and appetite stimulation. Monitor for hyperglycemia, psychiatric effects, infection risk. Do not continue indefinitely without clear comfort indication.^[52]
Haloperidol	Antipsychotic / Terminal delirium, refractory nausea	0.5–2 mg PO/SQ q6h PRN	For terminal delirium and agitation in the final days. Also useful for refractory nausea from opioids or AE-IPF. Low-dose is effective in frail, hypoxemic patients. Monitor for extrapyramidal symptoms. Have in comfort kit for terminal phase.^[30]
Furosemide	Loop diuretic / RHF edema	20–40 mg PO daily; SQ if oral absorption unreliable	For right heart failure edema from IPF-associated pulmonary hypertension. Titrate to comfort — ankle edema discomfort, skin stretch from severe edema, hepatic congestion. Diuresis target is edema comfort, not specific fluid balance.^[56]
Sildenafil	PDE-5 inhibitor / IPF-associated PH	20 mg PO TID	Continue if established and providing comfort benefit for dyspnea and RHF symptoms. Do not initiate in newly enrolled hospice patient without explicit comfort-benefit rationale. No significant interaction with opioids or benzodiazepines. ⚠ Monitor for hypotension, especially with concurrent antihypertensives.^[57]
Acetaminophen	Analgesic / Rib fracture pain, fever	500–1000 mg PO q6h scheduled	For rib fracture pain from chronic cough, fever from AE-IPF or infection, musculoskeletal pain from immobility. The rib fracture patient MUST have scheduled acetaminophen — PRN only is inadequate in a coughing patient. Treating rib pain relieves dyspnea (reduces splinting). Reduce to 500 mg q6h with hepatic congestion from cor pulmonale.^[42]
Loperamide	Antidiarrheal / Nintedanib GI management	2–4 mg PO PRN after each loose stool	Nintedanib diarrhea management — must be dispensed at enrollment if patient is on nintedanib. Diarrhea not managed with loperamide is the primary reason patients stop nintedanib. If continuing antifibrotic, provide the tools to make it tolerable.^[20]
Melatonin	Sleep aid / Nocturnal cough, sleep disruption	3–5 mg PO at bedtime	Sleep dysregulation, nocturnal cough arousal, nocturnal anxiety. No interaction with antifibrotic medications. No respiratory depressant. Safe adjunct. Patient whose nocturnal cough is partially treated by melatonin-enhanced deep sleep requires less daytime breakthrough opioid.^[46]

🌿 IPF Symptom Management Decision Tree

Evidence-based · Hospice-adapted · IPF-specific

Select a symptom below to begin

What is the primary symptom to address?

🚨 IPF Comfort Kit Must-Haves — Two Clinical Scenarios

The IPF comfort kit is organized around two clinical scenarios that are both certain to occur:^[30]

Chronic Daily Comfort Kit:

Morphine or codeine for daily use — prescribed, dispensed, dose documented
Lorazepam SL for acute anxiety-dyspnea crises
Fan positioned at bedside and directed correctly at face
Oxygen equipment checked and adequate supply confirmed
Loperamide if on nintedanib; bowel management protocol if on opioids

AE-IPF Emergency Kit:

Midazolam SQ — drawn, labeled, and stored in a clearly marked container. Family must know where it is and how to reach the nurse immediately to guide administration
Morphine SQ — as alternative to oral during AE-IPF when oral route compromised
Advance directive / POLST — physically in the home AND carried on the patient at all times
AE-IPF crisis plan POSTED: "If breathing becomes severely worse over hours — (1) Give morphine as instructed. (2) Give lorazepam as instructed. (3) Call the hospice nurse. (4) Do NOT call 911 unless the nurse instructs you to. The plan for this situation is already in place."

Oxygen Equipment Management Plan: Current flow rate for rest, exertion, and sleep documented. Oxygen company emergency contact posted. Backup cylinder supply adequate for 24 hours documented. HFNC troubleshooting contact if applicable.

S11Clinician

Clinician Pointers

High-yield clinical pearls for the IPF hospice team. The things not in the textbook — learned at the bedside over years of caring for patients whose lungs are turning to scar.

Prescribe opioids for both dyspnea AND cough at the first hospice visit

These are two separate clinical indications that opioids address through related but distinct mechanisms — central cough suppression via opioid receptors in the medullary cough center and dyspnea reduction via opioid receptor activity in the respiratory perception centers. Document both indications. The patient who reports severe dyspnea and severe cough requires a morphine dose that addresses both — the dose for dyspnea relief may be slightly higher than the dose that would be used for cough alone. Titrate to the combined symptom burden rather than the lower threshold. The patient still experiencing severe cough paroxysms causing rib fractures on the current opioid dose has not been adequately titrated for the cough component.^[28]^[37]

Exertional hypoxemia is catastrophically worse than the resting saturation suggests

Assess SpO₂ during the five steps from the chair to the bed at the first visit. In a patient maintaining SpO₂ of 93% at rest on 4 L/min, a 78% nadir with five steps of ambulation is not unusual and is not documented in most prior records. The oxygen prescription written based on resting saturation alone is likely inadequate for any activity. The exertional oxygen prescription must be separately assessed and documented. The patient who desaturates to 78% with any ambulation needs the hospice nurse to assess what oxygen flow rate maintains SpO₂ above 88% with that activity and to document the specific exertional prescription.^[32]^[34]

The AE-IPF crisis plan must be established at the first visit as if it will be needed next week

Because it might be. The acute exacerbation conversation in IPF is as urgent as the NIV withdrawal conversation in ALS-FTD. It must include: what AE-IPF looks like (sudden worsening of dyspnea over hours to days, new bilateral lung sounds, increasing oxygen requirement beyond the current maximum); what the family does when it happens (call the hospice nurse immediately, administer the comfort medications that are in the home, do not call 911 unless the nurse instructs after reviewing the advance directive); what the hospice nurse does (assess by phone and in person, initiate the comfort medication protocol, provide presence); and what the advance directive says about hospitalization for AE-IPF and invasive ventilation.^[49]^[53]

The transplant loss or near-miss is part of the clinical history — acknowledge it explicitly

Ask every IPF patient at enrollment: "Were you ever evaluated for a lung transplant? Were you listed?" If yes: "What was that experience like? Did you ever get a call that a donor was available? How did things go?" The answers will frequently reveal unprocessed grief, anger, relief, guilt, or hope that is specific to the transplant journey and has never been addressed in a clinical context. The hospice social worker and chaplain must be briefed on the transplant history because it shapes the patient's entire relationship to the disease and to their remaining time.^[64]^[75]

The cough assessment must be systematic and documented separately

Include: Leicester Cough Questionnaire (LCQ) score or equivalent severity rating; frequency of cough paroxysms; sleep disruption from nocturnal cough; urinary incontinence triggered by cough; and rib fracture history or current rib pain. If the patient winces or guards when they cough, assess for rib fracture with palpation over the lower lateral ribs and mid-chest — a positive finding requires analgesic escalation and documentation. The cough management plan must be documented separately from the dyspnea management plan even when opioids address both.^[39]^[40]

The antifibrotic continuation decision must be explicit — not inherited by inertia

Do not default to continuation by inertia or to discontinuation by clinical assumption. Present both options with accurate information: "You started this medication to slow the progression of the fibrosis; it may still be doing that. The disease is still advancing and will continue to advance. At this point, I want to ask you — how do you feel about the medication? Is it something you want to continue because it gives you something to do against the disease, or are the side effects making things harder in a way that makes you want to stop?" Accept the patient's answer and document it. If continuing, provide the tools to manage the side effects. If discontinuing, document the patient's reasons and your clinical agreement.^[15]^[22]

From the Field

Waldo Rios, NP

Hospice NP · 12+ Years

"The thing I see most often in IPF is the resting SpO₂ getting documented at every visit and the exertional SpO₂ never being checked. The patient is sitting in the recliner at 93% and everybody says the oxygen is fine. Walk them to the bathroom. Watch what happens. That number — the 76%, the 72% — that is the clinical truth of their oxygen prescription. And nobody has written a separate exertional order. That is where the gap is, and that is what the patient is living with every time they stand up."

— Waldo, NP · Terminal2

S12EveryoneClinician

Psychosocial & Spiritual Care

Existential distress, transplant loss grief, diagnostic odyssey anger, caregiver witness trauma, and the spiritual question of a body that cannot be fixed. The symptom burden you cannot see on a vitals sheet.

IPF produces a psychosocial burden that is distinct from cancer and from other terminal respiratory diseases. The combination of progressive breathlessness, oxygen dependence that confines the patient to the home, a cough that disrupts every social interaction and intimate moment, the absence of a known cause, and — for some — the devastating near-miss of a transplant that did not arrive in time creates a constellation of psychological suffering that is specific, identifiable, and treatable. The hospice team that addresses only the physical symptoms of IPF and does not open the psychosocial and spiritual domains has left the majority of the suffering untouched.^[73]^[74]

Existential Terror & Disease-Specific Grief

The Terror of Progressive Replacement

Grade B

The subjective experience of knowing that your lungs are being progressively and irreversibly replaced by scar tissue is among the most specific and profound existential horrors in all of medicine. It is not the abstraction of cancer cells growing somewhere in the body — it is the experience of the organ that delivers life to every cell becoming less capable of that function with every breath.^[74]

The patient who lies awake at night feeling their breathing become slightly more labored than last week is experiencing this replacement in real time
The hospice chaplain who can sit with this specific horror — who can ask "What is it like to be in this body, breathing this way, knowing what is happening to your lungs?" — creates space for a grief that is profoundly physical, profoundly intimate, and profoundly under-addressed in clinical settings
Screen for anxiety and depression at every visit — the anxiety-dyspnea cycle in IPF is a clinically treatable feedback loop where fear amplifies breathlessness and breathlessness amplifies fear^[76]

Transplant Near-Miss Grief

Grade C

For patients who were listed for lung transplant and did not receive one in time, the grief has a specific texture that is rarely addressed clinically:^[75]

The hope built and sustained through evaluation, listing, priority score monitoring, and waiting
The calls that came and went — the organ that went to someone sicker, the donor that was not a match, the patient who was too ill when the call came
The decision to delist, made or imposed — the transition from "waiting for lungs" to "waiting to die"
This transition is one of the most psychologically severe in all of palliative care. The social worker who asks "What was it like to wait? What happened when you got the call? What was it like when the list didn't work out?" provides care for a grief that is almost never clinically addressed^[78]

The Idiopathic Grief & Diagnostic Odyssey Anger

The "Why" That Has No Answer

The disease has no known cause in most cases. No smoking habit that explains it (in the 30–50% who never smoked heavily), no specific exposure, no genetic explanation. The word "idiopathic" means the cause is unknown.^[7]

The family who asks "why did this happen?" deserves an honest answer: "We genuinely do not know why this happens to some people and not others. There is no specific thing that caused it and no specific thing that could have prevented it. There is no one to blame, including the person who has the disease."
This answer, given clearly and compassionately, removes guilt and redirects the family's grief from causation to presence

Diagnostic Odyssey Anger

The average diagnostic delay in IPF is 2–3 years. Many patients were misdiagnosed with COPD, heart failure, or asthma and received treatments that were ineffective.^[6]

The anger about the years of wrong diagnosis is legitimate and must be acknowledged, not minimized
The patient who was treated for COPD for three years while their lungs were fibroting has a specific grief about lost time and lost opportunity for earlier antifibrotic treatment
Do not defend the diagnostic system. Acknowledge: "You're right that it took too long to get the right diagnosis. That happens more often than it should in this disease, and I understand the anger that comes with knowing the clock was running while the answer wasn't found."

Isolation, Intimacy & Caregiver Witness Trauma

Oxygen Dependence & Social Isolation

The IPF patient on 10–15 L/min is essentially homebound. The oxygen concentrator running 24 hours a day creates a radius of tubing that defines their world. Ambulatory cylinders at high flow rates provide 2–3 hours of compressed gas.^[76]
The social world has contracted to the house, the recliner, and the people who come to them
This isolation produces depression, anxiety, and existential suffering that compounds the physical suffering
The social worker who connects them to video visits, window visitors, and in-home companion visits provides a clinical intervention for isolation-related suffering

Cough, Intimacy & Body Image

The chronic severe cough prevents normal social interaction — phone conversations interrupted, family meals disrupted, sleep impossible in the same room^[39]
The spouse who has been sleeping separately for a year because the nocturnal cough makes sleep impossible has experienced a specific relational loss
Acknowledge it: "The cough has changed not just the physical experience of this disease but the relational one — your sleep, your conversations, your ability to be in the same room comfortably. That is a loss that deserves to be named alongside the physical ones."
Urinary incontinence from cough paroxysms produces shame and social withdrawal — assess directly and treat with incontinence products and pelvic floor referral if appropriate

Caregiver witness trauma: Watching a person you love lose their breath while you stand beside them is a specific form of caregiver trauma. The caregiver who lies awake listening to the cough, who watches the pulse oximeter readings drop with every step, who carries the fear that today might be the day the acute exacerbation arrives — is experiencing anticipatory grief that is compounded by witness helplessness. The hospice social worker who asks the caregiver directly, "What is it like for you to watch the breathing?" opens a clinical conversation that almost never happens and that caregivers almost universally need.^[77]

Spiritual Care in IPF

The theology of IPF is the theology of limits — the limits of medicine, the limits of the body, the limits of what can be hoped for. The patient who trusted medicine to find a treatment and was given medications that only slow the inevitable has a specific relationship to medical hope that may have been exhausted or transformed. The chaplain who can explore what hope looks like now — not hope for reversal, but hope for a good death, for enough time, for meaningful connection, for a death without air hunger — provides the reframe that clinical medicine cannot.^[73]

The question "What does a good day look like now?" is not resignation — it is the beginning of a different and more sustainable hope.

Clinical Pearl — Four Conversations at the First IPF Visit

In IPF, four conversations must happen at the first hospice visit or they will happen under duress later. (1) "I am prescribing morphine for your breathing and for your cough today. The evidence is clear that it is the most effective treatment for both. I am not waiting for things to get worse. The time to treat suffering is now." (2) "If your breathing suddenly gets much worse over a few hours — more than your usual bad day — that is an emergency we have planned for. The medications are in the house. The plan is posted. Call me before you call 911." (3) If transplant history: "I want to hear about the transplant experience — the waiting, what happened, how it ended. That experience is part of your story and it matters to what happens from here." (4) "The lungs are doing what this disease makes them do. Nothing you did caused this. Nothing you could have done would have stopped it. The word idiopathic means even medicine does not know why. There is nothing to blame and no one to blame. What there is now is time, and people who want to fill it with as much comfort and meaning as possible. That is what we are here for."

From the Field

Waldo Rios, NP

Hospice NP · 12+ Years

"The IPF patients I've had who carried it the hardest were the ones who were on the transplant list and didn't get the call. Not the ones who were never listed — they had time to adjust. The ones who waited, who felt their FVC dropping every three months, who had a pager or a phone that rang once for a donor that wasn't a match — and then were told they were too sick for surgery. That grief is surgical. And nobody at the transplant center addressed it because they were already managing the next patient. The social worker at hospice is the first person in the entire system who has the time to sit with it. Use that time."

— Waldo, NP · Terminal2

S13FamilyEveryone

Family Guide

Plain language for families. Share, print, or read aloud at the bedside. Covers oxygen management, cough care, the AE-IPF crisis plan, and what to do when breathlessness worsens.

You are caring for someone whose lungs are being slowly replaced by scar tissue. That sentence is hard to read and harder to live with. What we want you to know is that there are specific things we can do — and that you can do — to reduce the breathlessness, manage the cough, and plan for the emergencies before they happen. The medications are effective. The plan is in place. You are not alone in this, and you do not have to figure any of it out by yourself.^[73]

What You May See

Breathlessness that requires a lot of oxygen even at rest — your person's lungs are exchanging less and less oxygen through the scar tissue. The oxygen helps but cannot fully compensate. There are medications that significantly reduce the feeling of breathlessness even when the oxygen numbers don't change. Your nurse will ensure these are in place and adjusted at every visit.^[28]
Severe coughing spells that seem uncontrollable — the chronic cough of pulmonary fibrosis is caused by the scar tissue irritating the lung's nerve endings. It is not an infection and it does not mean the lungs are getting suddenly worse. There are medications specifically for this cough and your nurse will work to find the combination that reduces these episodes. Call the nurse if the cough is producing rib pain.^[39]
Rib pain with coughing — severe coughing can fracture ribs in people who have had steroid treatment or whose bones are thin from age. If your person says their ribs hurt when they cough, or if they are guarding their chest, call the nurse same day. Rib fractures are treatable and require specific pain management.^[42]
Breathlessness that suddenly and significantly worsens over a few hours (acute exacerbation) — this is the emergency we have planned for specifically. Go to the crisis plan posted in your home. Give the medications your nurse has reviewed. Call the hospice nurse immediately. Do not call 911 before calling the nurse unless the nurse cannot be reached within 10 minutes.^[49]
Increasing swelling in the ankles or legs — this can happen when the lungs put extra strain on the right side of the heart. There is medication that helps. Call the nurse if it is increasing rapidly or if the skin is breaking down.^[56]
Eating less and losing weight — the effort of breathing makes eating tiring. Offer small frequent meals. Let your person stop when they need to. The cough may make eating uncomfortable. Small bites, slow pacing.

How You Can Help

Direct the fan at your person's face during any dyspnea episode — this is medicine, not just comfort. It stimulates specific nerves that reduce the feeling of breathlessness. Keep a fan at every location where your person sits or lies.^[31]
Know the crisis medications and where they are before you need them — practice saying the names and doses when everything is calm. You do not want to be learning this during a crisis. The morphine, the lorazepam, the midazolam — know where each one is stored.
Keep the oxygen equipment clean and the supply adequate — check the cylinder supply weekly. Call the company before the last cylinder is used. Write down the flow rates for rest, walking, and sleep and post them on the equipment.
Sit with your person when they are breathless — speak calmly, breathe slowly yourself. Your calm is measurably calming to them. Presence reduces the fear component of breathlessness even when it cannot reduce the breathlessness itself.^[73]
Give cough medications on schedule — do not wait until the coughing is severe. The medications work best as prevention not rescue. Position your person upright during the worst cough periods — lying flat worsens cough in IPF. Honey one teaspoon at bedtime may reduce nocturnal cough.^[47]
Avoid any scented products near your person — candles, diffusers, air fresheners, eucalyptus oil — these can trigger severe coughing episodes in fibrotic lungs. Remove from the home environment.^[43]
If the transplant list was part of your journey — it is part of your story and your nurse and social worker want to hear it. The waiting, the hope, the loss. That experience shaped everything that came after and it matters.
Take care of yourself — watching someone you love lose their breath is one of the hardest things in caregiving. The fear you carry is proportionate to what you are facing. Call us when you need support — not just when the patient does.

🫁 Oxygen — Critical Information for Every Caregiver

Your person's oxygen flow rate is prescribed at specific settings for rest, for any walking, and for sleep — these may all be different. Write these settings down and post them on each piece of equipment.
When your person walks even a short distance — even to the bathroom — the oxygen requirement goes up significantly. Your nurse will tell you the correct flow rate for moving versus resting.
Do not increase the oxygen flow rate beyond what is prescribed without calling the nurse.
If the oxygen equipment stops working or makes an alarm — call the oxygen company AND the hospice nurse simultaneously.
Always have backup cylinders available. If your person is on a high-flow system: keep all connections clean and dry; the machine must run continuously; do not unplug.

🚨 AE-IPF Crisis Plan — Post This Where It Is Immediately Visible

If your person's breathing becomes SIGNIFICANTLY AND SUDDENLY WORSE (more than a bad day, happening over hours):

Step 1 — Give the morphine dose your nurse has prescribed
Step 2 — Give the lorazepam dose your nurse has prescribed
Step 3 — Sit your person upright, turn on the fan directed at their face
Step 4 — Call the hospice nurse immediately

IMPORTANT: Do not call 911 before calling the hospice nurse unless you cannot reach the nurse within 10 minutes. The plan for this crisis was built in advance. The medications in this house are the right medications for this situation. The hospital almost never helps in this situation and may cause harm inconsistent with your person's wishes. The advance directive and POLST are in this folder (location noted). Give this document to ANY medical provider who comes to this home.

📞 Call the nurse immediately if you see:

Sudden significant worsening of breathlessness over hours — follow AE-IPF crisis plan; call nurse immediately. Rib pain with coughing — call nurse same day; rib fracture assessment needed. Oxygen equipment failure — call oxygen company AND hospice nurse simultaneously. Fever above 101°F with worse breathing — call nurse same day; respiratory infection assessment needed. Sudden confusion or extreme sleepiness with breathing difficulty — call nurse immediately. Ankle swelling increasing rapidly or skin breakdown — call nurse same day. Coughing episodes producing urinary incontinence or becoming continuous — call nurse; cough medication adjustment needed.

🙏 You are living inside one of the most physically demanding caregiving situations in all of medicine. The oxygen equipment, the coughing through the night, the breathlessness that makes every movement an effort, the knowing that the lungs are changing — you are managing all of this alongside your grief and alongside your love. The fear you carry — the watching and listening for changes, the wondering every time the breathing sounds different — is proportionate to what you are facing. What we want you to know is that the plan is solid. The medications are in the house. The crisis instructions are posted. The nurse's number is within reach at every moment. You do not have to manage any of what comes next alone, and you do not have to decide anything in a moment of panic. We have already decided the important things together. Your job now — the only job that no one else can do — is to be present. Sit with them. Direct the fan. Breathe slowly. Say the things that need to be said while there is time to say them. The rest is covered.

S14Everyone

Waldo's Top 10 Tips

Clinical field wisdom from 12+ years at the bedside. The things you learn after doing this long enough. Not guidelines — real.

01

Prescribe opioids for dyspnea AND cough at the first visit as a combined comfort decision — not two separate referrals, not two separate visits, not after you've tried every inhaler and every antitussive and decided nothing else is working. At the first IPF hospice visit, the two central comfort problems are the breathlessness and the cough, and opioids address both. Start morphine 2.5–5 mg q4h and PRN. Document both indications in the note. The patient sitting across from you who is breathless at rest and coughing every three minutes has been undertreated for both symptoms for longer than this visit, and you can fix a significant portion of that suffering in the next forty-eight hours if you write the prescription today. Do not wait. The evidence is clear. The patient is suffering now.^[28]^[37]
02

Assess exertional SpO₂ at every visit — not just resting SpO₂. Stand up, walk with your patient from the chair to the bed or to the bathroom, watch the pulse oximeter. The number you see during that walk is the clinical reality of their oxygen management, not the number on the chart from last month's clinic visit. The patient who maintains 93% at rest on 4 L/min and drops to 76% walking five steps needs a separate exertional oxygen prescription and possibly a different delivery system. Write it, document it, call the oxygen company if the current equipment cannot meet the demand. The oxygen prescription that was written for rest is not the oxygen prescription for mobility in IPF. This gap between resting and exertional saturation is the single most under-documented clinical finding in IPF hospice care, and it is hiding in every patient you see.^[32]^[34]
03

The AE-IPF crisis plan must be in the home before the AE-IPF arrives. Write the plan, review it with the family, post it on the refrigerator. The midazolam must be prescribed and drawn and labeled and in the home before the first exacerbation. The morphine must be in the home. The advance directive must be physically present. The family must be able to recite what they do when the breathing suddenly gets severely worse — call the nurse before calling 911, give the morphine, give the lorazepam, sit the patient up, turn on the fan. The AE-IPF that arrives on a Tuesday afternoon can be at 50% mortality by Thursday. The comfort protocol that is in place on Monday is the one that works. The one you planned to set up at next week's visit is the one that doesn't exist when the family calls you at 2 AM in a panic.^[49]^[50]
04

Ask about the transplant journey and actually listen to the answer — not as checklist completion but as witnessing. "Were you on the transplant list? What was that like?" is a question that opens a chapter of the patient's experience of IPF that no one in the clinical system has probably asked about with the intent of actually sitting with the answer. The person who waited two years on the list, got a call for a donor organ that wasn't a match, watched their FVC decline while waiting, and was eventually told they were no longer a candidate has a grief about the transplant that is as significant as the grief about the disease. Hear it. Tell the social worker. It shapes every subsequent clinical and psychosocial interaction you will have with this patient and this family.^[75]^[78]
05

The cough that is causing rib fractures is a clinical emergency, not a side note. Examine the lower ribs at every visit with palpation. Ask the patient specifically: "Does it hurt when you cough? Do you feel or hear a cracking or popping sound when you cough?" The patient who answers yes to either has a rib fracture until proven otherwise. Treat it: scheduled acetaminophen, scheduled opioids for breakthrough pleuritic pain, positioning guidance. The rib fracture that is not treated causes the patient to splint — to guard the painful side with reduced respiratory effort — which restricts the already limited lung volume, worsens hypoxemia, and increases dyspnea. Treating the rib fracture pain treats the dyspnea. This is not a secondary problem. It is a primary comfort failure when it is missed.^[42]^[39]
06

Reassess the antifibrotic at the first visit and make the decision explicit. Do not inherit the antifibrotic prescription silently. Ask the patient: "The medication you have been on to slow the fibrosis — are you still getting any benefit from it? Are the side effects manageable? Does it feel important to you to be on it, or has that changed?" Accept whatever answer comes. If continuing, provide the tools to manage the side effects — loperamide for nintedanib diarrhea, sunscreen and GI support for pirfenidone. If discontinuing, document the patient's reasons and your clinical agreement. The antifibrotic that is causing more suffering than it is relieving is a comfort harm and the decision to stop it is a comfort intervention. Either way, the decision must be the patient's and it must be documented.^[15]^[22]
07

The fear of suffocation in IPF is a clinical target that requires a clinical name. Ask every IPF patient at the first visit: "When you're most breathless, is there a fear that comes with it? A fear that you might not be able to breathe?" The answer is almost universally yes in advanced IPF. That fear is the anxiety-dyspnea cycle and it is treatable. Lorazepam SL for acute panics. Mirtazapine for the background anxiety that is present even between dyspnea crises. The patient who is less afraid of breathlessness has less breathlessness — the feedback loop runs in both directions and treating the anxiety reduces the dyspnea. Say it explicitly: "There is a medication for the fear part of this, not just the breathing part, and I am going to prescribe it today." That sentence changes the visit.^[35]^[76]
08

Establish the oxygen supply chain as a clinical assessment item at every visit. How many cylinders are in the house? When was the last delivery? Is the concentrator filter clean? Is the HFNC humidifier reservoir full and the tubing intact? The IPF patient who runs out of ambulatory cylinder oxygen on a Sunday afternoon and cannot reach the oxygen company is experiencing a preventable comfort failure. The hospice nurse who does not assess the oxygen supply at every visit has missed one of the most practically important comfort assessments in IPF. Document the supply status in the visit note. Call the oxygen company proactively if the supply is running low. This is not logistics — this is clinical care for a patient whose life depends on that equipment every minute of every day.^[32]
09

Prepare the family for what AE-IPF looks like before it happens. Tell them specifically: the breathing will get worse over hours, not over days. The feeling will be of severe air hunger. The comfort medications that are in the house — the morphine and the midazolam — will reduce the air hunger. This is what hospice is for. They do not have to watch this happen without any ability to act. They have been given tools and a plan and a nurse to call. The family who has had this conversation is not standing beside a person in air hunger thinking "there is nothing I can do." They are thinking "I know exactly what to do and I am doing it." That shift — from helplessness to action — is the most important thing you give the IPF family at the first visit. It does not prevent the crisis. It prevents the psychological destruction of the caregiver during the crisis.^[73]^[77]
10

Say the idiopathic thing. At the first IPF visit, say it out loud: "The word idiopathic in your diagnosis means we do not know why this happened to you. There is no specific exposure they've identified, no specific thing you did. For the 30 to 40 percent of people with this disease who never smoked heavily or who had none of the usual risk factors, there is literally no explanation that medicine can offer. That is one of the hardest things about this disease — there is no one to be angry at and nothing to have done differently. And I want to say that clearly because I think you may have been carrying a question about why that medicine has not answered. What I do know is that what is happening in your lungs is not a consequence of anything that defines you or that you deserve. It is the intersection of biology and chance, and the work we are doing together now is everything that matters." Say it first. Say it clearly. They have been waiting for someone to say it.^[7]^[74]

— Waldo, NP

REFClinician

References

Peer-reviewed citations supporting all clinical content. Based on articles retrieved from PubMed. All PMIDs hyperlinked. Evidence levels assigned by study design.

Raghu G, Weycker D, Edelsberg J, et al. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2006;174(7):810-816.

PMID 16809633 DOIObservational

Navaratnam V, Fleming KM, West J, et al. The rising incidence of idiopathic pulmonary fibrosis in the U.K. Thorax. 2011;66(6):462-467.

PMID 21525528 DOIObservational

Hutchinson J, Fogarty A, Hubbard R, et al. Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review. Eur Respir J. 2015;46(3):795-806.

PMID 25976683 DOISystematic Review

Ley B, Ryerson CJ, Vittinghoff E, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med. 2012;156(10):684-691.

PMID 22586007 DOIObservational

Navaratnam V, Hubbard R. The mortality burden of idiopathic pulmonary fibrosis in the United Kingdom. Am J Respir Crit Care Med. 2019;200(2):256-258.

PMID 30973756 DOIObservational

Hutchinson JP, McKeever TM, Fogarty AW, et al. Increasing global mortality from idiopathic pulmonary fibrosis in the 21st century. Ann Am Thorac Soc. 2014;11(8):1176-1185.

PMID 25165873 DOIObservational

Esposito DB, Lanes S, Engel T, et al. Incidence and prevalence of idiopathic pulmonary fibrosis in US adults 18–64 years old. Eur Respir J. 2016;48(1):179-186.

PMID 27126689 DOIObservational

Lamas DJ, Kawut SM, Baez ER, et al. Delayed access and survival in idiopathic pulmonary fibrosis: a cohort study. Am J Respir Crit Care Med. 2011;184(7):842-847.

PMID 21719755 DOIObservational

Lederer DJ, Martinez FJ. Idiopathic pulmonary fibrosis. N Engl J Med. 2018;378(19):1811-1823.

PMID 29742380 DOIReview

Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788-824.

PMID 21471066 DOIGuideline

Raghu G, Remy-Jardin M, Richeldi L, et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2022;205(9):e18-e47.

PMID 35486072 DOIGuideline

Raghu G, Rochwerg B, Zhang Y, et al. An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am J Respir Crit Care Med. 2015;192(2):e3-e19.

PMID 26177183 DOIGuideline

Flaherty KR, King TE Jr, Raghu G, et al. Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis? Am J Respir Crit Care Med. 2004;170(8):904-910.

PMID 15256390 DOIObservational

Flaherty KR, Andrei AC, King TE Jr, et al. Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis? Am J Respir Crit Care Med. 2007;175(10):1054-1060.

PMID 17255566 DOIObservational

Cottin V, Nunes H, Brillet PY, et al. Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur Respir J. 2005;26(4):586-593.

PMID 16204587 DOIObservational

Lettieri CJ, Veerappan GR, Helman DL, et al. Outcomes and safety of surgical lung biopsy for interstitial lung disease. Chest. 2005;127(5):1600-1606.

PMID 15888834 DOIObservational

Lynch DA, Sverzellati N, Travis WD, et al. Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society white paper. Lancet Respir Med. 2018;6(2):138-153.

PMID 29154106 DOIExpert Consensus

Meyer KC, Raghu G, Baughman RP, et al. An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med. 2012;185(9):1004-1014.

PMID 22550210 DOIGuideline

Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071-2082.

PMID 24836310 DOIRCT

King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083-2092.

PMID 24836312 DOIRCT

Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377(9779):1760-1769.

PMID 21571362 DOIRCT

Raghu G, Anstrom KJ, King TE Jr, et al. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med. 2012;366(21):1968-1977.

PMID 22607134 DOIRCT

Richeldi L, Cottin V, du Bois RM, et al. Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS trials. Respir Med. 2016;113:74-79.

PMID 26915984 DOIMeta-Analysis

Richeldi L, Kolb M, Jouneau S, et al. Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis. BMC Pulm Med. 2020;20(1):3.

PMID 31900127 DOIRCT

Nathan SD, Albera C, Bradford WZ, et al. Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis. Lancet Respir Med. 2017;5(1):33-41.

PMID 27876247 DOIMeta-Analysis

Maher TM, Corte TJ, Fischer A, et al. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2020;8(2):147-157.

PMID 31578169 DOIRCT

Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019;381(18):1718-1727.

PMID 31566307 DOIRCT

Vancheri C, Kreuter M, Richeldi L, et al. Nintedanib with add-on pirfenidone in idiopathic pulmonary fibrosis. Results of the INJOURNEY trial. Am J Respir Crit Care Med. 2018;197(3):356-363.

PMID 28889759 DOIRCT

Cottin V, Maher T. Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis. Eur Respir Rev. 2015;24(135):58-64.

PMID 25726556 DOIReview

Kreuter M, Swigris J, Engel T, et al. Discontinuation of antifibrotic therapy in IPF: a post hoc analysis of the INPULSIS trials. Eur Respir J. 2019;54(3):1900390.

PMID 31273038 DOIRCT

Raghu G, Collard HR, Anstrom KJ, et al. Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med. 2012;185(10):1044-1048.

PMID 22505745 DOIExpert Consensus

Visca D, Mori L, Tsipouri V, et al. Effect of ambulatory oxygen on quality of life for patients with fibrotic lung disease (AmbOx): a prospective, open-label, mixed-method, crossover randomised controlled trial. Lancet Respir Med. 2018;6(10):759-770.

PMID 30170904 DOIRCT

Lama VN, Flaherty KR, Toews GB, et al. Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. Am J Respir Crit Care Med. 2003;168(9):1084-1090.

PMID 12917227 DOIObservational

Hallstrand TS, Boitano LJ, Johnson WC, et al. The timed walk test as a measure of severity and survival in idiopathic pulmonary fibrosis. Eur Respir J. 2005;25(1):96-103.

PMID 15640329 DOIObservational

Flaherty KR, Andrei AC, Murray S, et al. Idiopathic pulmonary fibrosis: prognostic value of changes in physiology and six-minute walk test. Am J Respir Crit Care Med. 2006;174(7):803-809.

PMID 16825656 DOIObservational

Lettieri CJ, Nathan SD, Browning RF, et al. The distance-saturation product predicts mortality in idiopathic pulmonary fibrosis. Respir Med. 2006;100(10):1734-1741.

PMID 16545950 DOIObservational

Nishiyama O, Taniguchi H, Kondoh Y, et al. A simple assessment of dyspnoea as a prognostic indicator in idiopathic pulmonary fibrosis. Eur Respir J. 2010;36(5):1067-1072.

PMID 20413545 DOIObservational

Visca D, Montgomery A, de Lauretis A, et al. Ambulatory oxygen in interstitial lung disease. Eur Respir J. 2011;38(4):987-990.

PMID 21965506 DOIObservational

Koyauchi T, Hasegawa H, Kanata K, et al. Efficacy and tolerability of high-flow nasal cannula oxygen therapy for hypoxemic respiratory failure in patients with interstitial lung disease with do-not-intubate orders: a retrospective single-center study. Respiration. 2018;96(4):323-329.

PMID 29972820 DOIObservational

Abernethy AP, Currow DC, Frith P, et al. Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. BMJ. 2003;327(7414):523-528.

PMID 12958109 DOIRCT

Currow DC, McDonald C, Oaten S, et al. Once-daily opioids for chronic dyspnea: a dose increment and pharmacovigilance study. J Pain Symptom Manage. 2011;42(3):388-399.

PMID 21458217 DOIObservational

Jennings AL, Davies AN, Higgins JP, et al. A systematic review of the use of opioids in the management of dyspnoea. Thorax. 2002;57(11):939-944.

PMID 12403875 DOISystematic Review

Barnes H, McDonald J, Smallwood N, et al. Opioids for the palliation of refractory breathlessness in adults with advanced disease and terminal illness. Cochrane Database Syst Rev. 2016;3(3):CD011008.

PMID 27030166 DOISystematic Review

Galbraith S, Fagan P, Perkins P, et al. Does the use of a handheld fan improve chronic dyspnea? A randomized, controlled, crossover trial. J Pain Symptom Manage. 2010;39(5):831-838.

PMID 20471544 DOIRCT

Ekström M, Bajwah S, Bland JM, et al. One evidence base; three stories: do opioids relieve chronic breathlessness? Thorax. 2018;73(1):88-90.

PMID 28754811 DOIReview

Currow D, Louw S, McCloud P, et al. Regular, sustained-release morphine for chronic breathlessness: a multicentre, double-blind, randomised, placebo-controlled trial. Thorax. 2020;75(1):50-56.

PMID 31594787 DOIRCT

Verberkt CA, van den Beuken-van Everdingen MHJ, Schols JMGA, et al. Effect of sustained-release morphine for refractory breathlessness in chronic obstructive pulmonary disease on health status: a randomized clinical trial. JAMA Intern Med. 2020;180(10):1306-1314.

PMID 32804188 DOIRCT

Maddocks M, Lovell N, Booth S, et al. Palliative care and management of troublesome symptoms for people with chronic obstructive pulmonary disease. Lancet. 2017;390(10098):988-1002.

PMID 28351543 DOIReview

Simon ST, Higginson IJ, Booth S, et al. Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults. Cochrane Database Syst Rev. 2016;10(10):CD007354.

PMID 27764523 DOISystematic Review

Higginson IJ, Bausewein C, Reilly CC, et al. An integrated palliative and respiratory care service for patients with advanced disease and refractory breathlessness: a randomised controlled trial. Lancet Respir Med. 2014;2(12):979-987.

PMID 25465642 DOIRCT

Horton MR, Santopietro V, Mathew L, et al. Thalidomide for the treatment of cough in idiopathic pulmonary fibrosis: a randomized trial. Ann Intern Med. 2012;157(6):398-406.

PMID 22986377 DOIRCT

Verberkt CA, van den Beuken-van Everdingen MHJ, Franssen FME, et al. Opioids for chronic cough: a systematic review. Eur Respir J. 2021;58(6):2101509.

PMID 34649976 DOISystematic Review

Ryan NM, Birring SS, Gibson PG. Gabapentin for refractory chronic cough: a randomised, double-blind, placebo-controlled trial. Lancet. 2012;380(9853):1583-1589.

PMID 22951084 DOIRCT

Birring SS, Prudon B, Carr AJ, et al. Development of a symptom specific health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ). Thorax. 2003;58(4):339-343.

PMID 12668799 DOIObservational

Key AL, Holt K, Hamilton A, et al. Objective cough frequency in idiopathic pulmonary fibrosis. Cough. 2010;6(1):4.

PMID 20529330 DOIObservational

Madison JM, Irwin RS. Chronic cough in adults with interstitial lung disease. Curr Opin Pulm Med. 2005;11(5):412-416.

PMID 16093815 DOIReview

Morice AH, Millqvist E, Bieksiene K, et al. ERS guidelines on the diagnosis and treatment of chronic cough in adults and children. Eur Respir J. 2020;55(1):1901136.

PMID 31515408 DOIGuideline

Morice AH, Fontana GA, Belvisi MG, et al. ERS guidelines on the assessment of cough. Eur Respir J. 2007;29(6):1256-1276.

PMID 17540788 DOIGuideline

Morell F, Roger A, Reyes L, et al. Bird fancier's lung: a series of 86 patients. Medicine (Baltimore). 2008;87(2):110-130.

PMID 18344808 DOIObservational

Morice AH, Jakes AD, Faruqi S, et al. A worldwide survey of chronic cough: a manifestation of enhanced somatosensory response. Eur Respir J. 2014;44(5):1149-1155.

PMID 25186267 DOIObservational

Morice AH, Menon MS, Mulrennan SA, et al. Opiate therapy in chronic cough. Am J Respir Crit Care Med. 2007;175(4):312-315.

PMID 17122382 DOIRCT

Collard HR, Ryerson CJ, Corte TJ, et al. Acute exacerbation of idiopathic pulmonary fibrosis. An international working group report. Am J Respir Crit Care Med. 2016;194(3):265-275.

PMID 27299520 DOIExpert Consensus

Song JW, Hong SB, Lim CM, et al. Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur Respir J. 2011;37(2):356-363.

PMID 20595144 DOIObservational

Kondoh Y, Taniguchi H, Katsuta T, et al. Risk factors of acute exacerbation of idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis. 2010;27(2):103-110.

PMID 21319592Observational

Agarwal R, Jindal SK. Acute exacerbation of idiopathic pulmonary fibrosis: a systematic review. Eur J Intern Med. 2008;19(4):227-235.

PMID 18471669 DOISystematic Review

Stern JB, Mal H, Groussard O, et al. Prognosis of patients with advanced idiopathic pulmonary fibrosis requiring mechanical ventilation for acute respiratory failure. Chest. 2001;120(1):213-219.

PMID 11451840 DOIObservational

Al-Hameed FM, Sharma S. Outcome of patients admitted to the intensive care unit for acute exacerbation of idiopathic pulmonary fibrosis. Can Respir J. 2004;11(2):117-122.

PMID 15045042 DOIObservational

Mollica C, Paone G, Conti V, et al. Mechanical ventilation in patients with end-stage idiopathic pulmonary fibrosis. Respiration. 2010;79(3):209-215.

PMID 19786729 DOIObservational

Johannson KA, Vittinghoff E, Lee K, et al. Acute exacerbation of idiopathic pulmonary fibrosis associated with air pollution exposure. Eur Respir J. 2014;43(4):1124-1131.

PMID 24176998 DOIObservational

Collard HR, Moore BB, Flaherty KR, et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2007;176(7):636-643.

PMID 17585107 DOIExpert Consensus

Zisman DA, Schwarz M, Anstrom KJ, et al. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med. 2010;363(7):620-628.

PMID 20484178 DOIRCT

Han MK, Bach DS, Hagan PG, et al. Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction. Chest. 2013;143(6):1699-1708.

PMID 23732584 DOIRCT

Lettieri CJ, Nathan SD, Barnett SD, et al. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest. 2006;129(3):746-752.

PMID 16537877 DOIObservational

Nathan SD, Barbera JA, Gaine SP, et al. Pulmonary hypertension in chronic lung disease and hypoxia. Eur Respir J. 2019;53(1):1801914.

PMID 30545976 DOIReview

Cottin V, Le Pavec J, Prevot G, et al. Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome. Eur Respir J. 2010;35(1):105-111.

PMID 19643948 DOIObservational

Kolb M, Raghu G, Wells AU, et al. Nintedanib plus sildenafil in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2018;379(18):1722-1731.

PMID 30220235 DOIRCT

Shorr AF, Wainright JL, Cors CS, et al. Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant. Eur Respir J. 2007;30(4):715-721.

PMID 17626111 DOIObservational

Seibold MA, Wise AL, Speer MC, et al. A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med. 2011;364(16):1503-1512.

PMID 21506741 DOIObservational

Armanios MY, Chen JJ, Cogan JD, et al. Telomerase mutations in families with idiopathic pulmonary fibrosis. N Engl J Med. 2007;356(13):1317-1326.

PMID 17392301 DOIObservational

Tsakiri KD, Cronkhite JT, Kishi PJ, et al. Adult-onset pulmonary fibrosis caused by mutations in telomerase. Proc Natl Acad Sci U S A. 2007;104(18):7552-7557.

PMID 17460043 DOIObservational

Newton CA, Batra K, Torrealba J, et al. Telomere-related lung fibrosis is diagnostically heterogeneous but uniformly progressive. Eur Respir J. 2016;48(6):1710-1720.

PMID 27540018 DOIObservational

Fingerlin TE, Murphy E, Zhang W, et al. Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis. Nat Genet. 2013;45(6):613-620.

PMID 23583980 DOIObservational

Kropski JA, Blackwell TS, Loyd JE. The genetic basis of idiopathic pulmonary fibrosis. Eur Respir J. 2015;45(6):1717-1727.

PMID 25837031 DOIReview

Thabut G, Mal H, Castier Y, et al. Survival benefit of lung transplantation for patients with idiopathic pulmonary fibrosis. J Thorac Cardiovasc Surg. 2003;126(2):469-475.

PMID 12928646 DOIObservational

Schaffer JM, Singh SK, Reitz BA, et al. Single- vs double-lung transplantation in patients with chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis since the implementation of lung allocation score. JAMA. 2015;313(9):936-948.

PMID 25734735 DOIObservational

Egan TM, Murray S, Bustami RT, et al. Development of the new lung allocation system in the United States. Am J Transplant. 2006;6(5 Pt 2):1212-1227.

PMID 16613597 DOIObservational

Weill D, Benden C, Corris PA, et al. A consensus document for the selection of lung transplant candidates: 2014—an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2015;34(1):1-15.

PMID 25085497 DOIExpert Consensus

Verleden GM, Glanville AR, Lease ED, et al. Chronic lung allograft dysfunction: definition, diagnostic criteria, and approaches to treatment—a consensus report from the Pulmonary Council of the ISHLT. J Heart Lung Transplant. 2019;38(5):493-503.

PMID 30962148 DOIExpert Consensus

Kapnadak SG, Raghu G. Lung transplantation for interstitial lung disease. Eur Respir Rev. 2021;30(161):210017.

PMID 34348979 DOIReview

Lindell KO, Liang Z, Hoffman LA, et al. Palliative care and location of death in decedents with idiopathic pulmonary fibrosis. Chest. 2015;147(2):423-429.

PMID 25187973 DOIObservational

Lindell KO, Kavalieratos D, Gibson KF, et al. The palliative care needs of patients with idiopathic pulmonary fibrosis: a qualitative study of patients and family caregivers. Heart Lung. 2017;46(1):24-29.

PMID 27871724 DOIObservational

Bajwah S, Higginson IJ, Ross JR, et al. The palliative care needs for fibrotic interstitial lung disease: a qualitative study of patients, informal caregivers and health professionals. Palliat Med. 2013;27(9):869-876.

PMID 23885010 DOIObservational

Kreuter M, Bendstrup E, Russell AM, et al. Palliative care in interstitial lung disease: living well. Lancet Respir Med. 2017;5(12):968-980.

PMID 28993108 DOIReview

Swigris JJ, Stewart AL, Gould MK, et al. Patients' perspectives on how idiopathic pulmonary fibrosis affects the quality of their lives. Health Qual Life Outcomes. 2005;3:61.

PMID 16212668 DOIObservational

Rajala K, Lehto JT, Saarinen M, et al. End-of-life care of patients with idiopathic pulmonary fibrosis. BMC Palliat Care. 2016;15(1):85.

PMID 27756286 DOIObservational

Ahmadi Z, Wysham NG, Lundström S, et al. End-of-life care in oxygen-dependent ILD compared with lung cancer: a national population-based study. Thorax. 2016;71(6):510-516.

PMID 26865603 DOIObservational

Janssen K, Rosielle D, Wang Q, et al. The impact of palliative care on quality of life, anxiety, and depression in idiopathic pulmonary fibrosis: a randomized controlled pilot study. Respir Res. 2020;21(1):2.

PMID 31900175 DOIRCT

Lee YJ, Choi SM, Lee YJ, et al. Clinical impact of depression and anxiety in patients with idiopathic pulmonary fibrosis. PLoS One. 2017;12(9):e0184300.

PMID 28898283 DOIObservational

Ryerson CJ, Berkeley J, Carrieri-Kohlman VL, et al. Depression and functional status are strongly associated with dyspnea in interstitial lung disease. Chest. 2011;139(3):609-616.

PMID 20688924 DOIObservational

100

Belkin A, Albright K, Swigris JJ. A qualitative study of informal caregivers' perspectives on the effects of idiopathic pulmonary fibrosis. BMJ Open Respir Res. 2014;1(1):e000007.

PMID 25478168 DOIObservational

101

Russell AM, Ripamonti E, Vancheri C. Qualitative European survey of patients with idiopathic pulmonary fibrosis: patients' perspectives of the disease and treatment. BMC Pulm Med. 2016;16(1):10.

PMID 26762154 DOIObservational

102

Overgaard D, Kaldan G, Marsaa K, et al. The lived experience with idiopathic pulmonary fibrosis: a qualitative study. Eur Respir J. 2016;47(5):1472-1480.

PMID 26846834 DOIObservational

103

Duck A, Spencer LG, Bailey S, et al. Perceptions, experiences and needs of patients with idiopathic pulmonary fibrosis. J Adv Nurs. 2015;71(5):1055-1065.

PMID 25533573 DOIObservational

104

Sano A, Tashiro K, Fukuda T. Cough-induced rib fractures. Asian Cardiovasc Thorac Ann. 2015;23(3):255-260.

PMID 16007893 DOIObservational

105

French CT, Fletcher KE, Irwin RS. A comparison of gender differences in health-related quality of life in acute and chronic coughers. Chest. 2005;127(6):1991-1998.

PMID 15947312 DOIObservational

106

Dicpinigaitis PV, Tso R, Banauch G. Prevalence of depressive symptoms among patients with chronic cough. Chest. 2006;130(6):1839-1843.

PMID 17167006 DOIObservational

107

Dicpinigaitis PV, Lim L, Banauch GI. Cough syncope. Respir Med. 2014;108(2):244-251.

PMID 24238768 DOIReview

108

Raghu G, Freudenberger TD, Yang S, et al. High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis. Eur Respir J. 2006;27(1):136-142.

PMID 16387946 DOIObservational

109

Lee JS, Ryu JH, Elicker BM, et al. Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;184(12):1390-1394.

PMID 21700909 DOIObservational

110

Lee JS, Collard HR, Anstrom KJ, et al. Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials. Lancet Respir Med. 2013;1(5):369-376.

PMID 24429201 DOIObservational

111

Raghu G, Pellegrini CA, Yow E, et al. Laparoscopic anti-reflux surgery for the treatment of idiopathic pulmonary fibrosis (WRAP-IPF): a multicentre, randomised, controlled phase 2 trial. Lancet Respir Med. 2018;6(9):707-714.

PMID 30100404 DOIRCT

112

Raghu G, Yang ST, Spada C, et al. Sole treatment of acid gastroesophageal reflux in idiopathic pulmonary fibrosis: a case series. Chest. 2006;129(3):794-800.

PMID 16537884 DOIObservational

113

Dowman L, Hill CJ, May A, et al. Pulmonary rehabilitation for interstitial lung disease. Cochrane Database Syst Rev. 2021;2(2):CD006322.

PMID 34559419 DOISystematic Review

114

Holland AE, Hill CJ, Conron M, et al. Short term improvement in exercise capacity and symptoms following exercise training in interstitial lung disease. Thorax. 2008;63(6):549-554.

PMID 18245143 DOIRCT

115

Vainshelboim B, Oliveira J, Yehoshua L, et al. Exercise training-based pulmonary rehabilitation program is clinically beneficial for idiopathic pulmonary fibrosis. Respiration. 2014;88(5):378-388.

PMID 25341682 DOIRCT

116

Holland AE, Mahal A, Hill CJ, et al. Home-based rehabilitation for COPD using minimal resources: a randomised, controlled equivalence trial. Thorax. 2017;72(1):57-65.

PMID 27672116 DOIRCT

117

Raghu G, Amatto VC, Behr J, et al. Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review. Eur Respir J. 2015;46(4):1113-1130.

PMID 26424523 DOISystematic Review

terminal2.care content is for educational purposes and is not a substitute for clinical judgment. Based on articles retrieved from PubMed. © Terminal2 | terminal2.care

📝

Private Notes

Session notes — not saved to any server. Clears when you close the tab.

Use this space for visit notes, clinical reminders, or patient-specific observations. This text is stored only in your browser session.